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Abstract
Background: With the increasing number of genomic sequencing studies, hundreds of genes have been
implicated in neurodevelopmental disorders (NDDs). The rate of gene discovery far outpaces our understanding of
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genotype–phenotype correlations, with clinical characterization remaining a bottleneck for understanding NDDs.
Most disease-associated Mendelian genes are members of gene families, and we hypothesize that those with
related molecular function share clinical presentations.
Methods: We tested our hypothesis by considering gene families that have multiple members with an enrichment
of de novo variants among NDDs, as determined by previous meta-analyses. One of these gene families is the
heterogeneous nuclear ribonucleoproteins (hnRNPs), which has 33 members, five of which have been recently
identified as NDD genes (HNRNPK, HNRNPU, HNRNPH1, HNRNPH2, and HNRNPR) and two of which have significant
enrichment in our previous meta-analysis of probands with NDDs (HNRNPU and SYNCRIP). Utilizing protein
homology, mutation analyses, gene expression analyses, and phenotypic characterization, we provide evidence for
variation in 12 HNRNP genes as candidates for NDDs. Seven are potentially novel while the remaining genes in the
family likely do not significantly contribute to NDD risk.
Results: We report 119 new NDD cases (64 de novo variants) through sequencing and international collaborations
and combined with published clinical case reports. We consider 235 cases with gene-disruptive single-nucleotide
variants or indels and 15 cases with small copy number variants. Three hnRNP-encoding genes reach nominal or
exome-wide significance for de novo variant enrichment, while nine are candidates for pathogenic mutations.
Comparison of HNRNP gene expression shows a pattern consistent with a role in cerebral cortical development
with enriched expression among radial glial progenitors. Clinical assessment of probands (n = 188–221) expands the
phenotypes associated with HNRNP rare variants, and phenotypes associated with variation in the HNRNP genes
distinguishes them as a subgroup of NDDs.
Conclusions: Overall, our novel approach of exploiting gene families in NDDs identifies new HNRNP-related
disorders, expands the phenotypes of known HNRNP-related disorders, strongly implicates disruption of the hnRNPs
as a whole in NDDs, and supports that NDD subtypes likely have shared molecular pathogenesis. To date, this is the
first study to identify novel genetic disorders based on the presence of disorders in related genes. We also perform
the first phenotypic analyses focusing on related genes. Finally, we show that radial glial expression of these genes
is likely critical during neurodevelopment. This is important for diagnostics, as well as developing strategies to best
study these genes for the development of therapeutics.
Keywords: Neurodevelopmental disorders, hnRNPs, Cortex development, Gene families
Background
Among the hundreds of candidate genes proposed for
neurodevelopmental disorders (NDDs), genes involved
in RNA metabolic processing and regulation of gene ex-
pression have been shown to be enriched for de novo
variants (DNVs) among probands with NDDs [1]. RNA
processing (splicing, transport, localization, translation,
and degradation) is critically important for brain devel-
opment and function, as neurons are post-mitotic cells
dependent on RNA expression, as well as spatiotemporal
isoform specificity, for individual growth and functional-
ity [2]. To successfully regulate RNA processing and
protein synthesis, over 500 RNA-binding proteins (RBPs)
in humans are abundantly and ubiquitously expressed,
found primarily in the nucleus [3]. Although ubiquitous,
there are tissue-specific changes in alternative splicing
from RBPs resulting in cell-specific phenotypes [4]. As
RBPs are necessary for many steps of neuronal RNA me-
tabolism, there are multiple opportunities for dysfunc-
tion, which is highlighted by the range of neurological
phenotypes resulting from variation in RBP-encoding
genes, including neurodegenerative diseases, muscular
atrophies, and various cancers. RBPs have also been im-
plicated in NDDs, most notably FMR1 in fragile X
syndrome.
Here, we hypothesize that variation in gene families
with related structure and function in the brain will re-
sult in subtypes of NDDs with related pathology. With
over 80% of Mendelian disease-associated genes being
part of gene families and/or having functionally redun-
dant paralogs, this provides an opportunity to divide
many NDD candidate genes into subgroups [5, 6]. In
fact, it has recently been shown that DNVs are enriched
among a subset of gene families in probands with NDDs
[7]. This approach aids in understanding the biological
impacts of variation in groups of genes, provides an op-
portunity for gene discovery, and allows for development
of gene/protein family-specific therapeutics impacting a
larger number of individuals than when targeting a
single gene.
Focusing on RNA processing, we applied this gene
family approach to identify gene families implicated in
NDDs. Of the four gene families identified from previous
meta-analyses of NDD exomes, the heterogeneous
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nuclear ribonucleoproteins (hnRNPs for proteins,
HNRNPs for genes) stand out as strong NDD candidate
genes that have yet to be fully investigated, as the fewest
members of the family are associated with known disor-
ders (Table 1). The hnRNPs are a large family of RBPs
consisting of 33 core and minor members implicated in
many steps of RNA processing. Several, primarily
through changes in expression or localization, have been
associated with neurodegenerative disorders, and, more
recently, five (HNRNPH1, HNRNPH2, HNRNPK, HNRN
PR, and HNRNPU) have been described as having DNVs
among probands with NDDs (Table 2). We have also
previously shown that two HNRNPs (HNRNPU and
SYNCRIP) have a significant enrichment of DNVs
among probands with NDDs, making them very strong
candidate genes [1]. Supporting their role in NDDs as a
gene family, it is known that hnRNPs function coopera-
tively and compensatorily, suggesting that disruption
among them may result in similar phenotypic conse-
quences. Thus, we hypothesize that there may be add-
itional hnRNPs with shared structure and function that
impact neurodevelopment, resulting in shared pheno-
types. Overall, the hnRNPs are just one example of how
multiple members of a gene family can be involved in
related NDDs. Recent data from large-scale sequencing
efforts suggest that other gene families (e.g., chromodo-
main DNA-binding helicase gene family) may benefit
from similar coordinated investigations.
Here, through international collaborations, protein,
mutation and expression analyses, and an exhaustive lit-
erature search, we identify additional HNRNPs with
pathogenic likely gene-disrupting (LGD) and severe mis-
sense single-nucleotide variants (SNVs), indels, or small
copy number variants (CNVs) among probands with
NDDs while utilizing novel methods of grouping genetic
disorders by gene family instead of broader gene func-
tion. We compare findings from a total of 250 probands
with NDDs with de novo or likely de novo SNVs/CNVs:
122 novel cases (118 SNVs or small indels and four
chromosomal deletions) and 128 published probands
(117 SNVs or small indels and 11 CNVs). Of these, 240
probands have variants occurring in 12 HNRNPs where
three or more probands have been identified (termed
NDD HNRNPs: HNRNPAB, HNRNPD, HNRNPF, HNRN
PH1, HNRNPH2, HNRNPH3, HNRNPK, HNRNPR,
SYNCRIP, HNRNPU, HNRNPUL1, and HNRNPUL2).
We establish variation in a subset of the HNRNPs as a
risk factor for NDDs and highlight the utility of a gene
family-based approach to identify NDD-related
disorders.
Methods
Identification of candidate NDD HNRNPs
Literature review to determine NDD candidate HNRNPs
First, HNRNPs with published cases were identified in
large exome or genome sequencing studies, as identified
by denovo-db v1.6 or case reports found by searching
PubMed with all known gene aliases (n = 128; Fig. 1,
Additional File 1: Table S1) [11–18, 20–61]. Cohorts in
denovo-db v1.6 include ASD samples (n = 5886: includ-
ing the Simons Simplex collection [SSC, n = 2508] and
MSSNG [n = 1625]), DD/ID samples (n = 1010), and epi-
lepsy samples (n = 532, including the Epi4K Consortium
[n = 264]). Samples were also identified from the Autism
Sequencing Consortium (ASC, n = 8157) and the Epi-
lepsy Genetics Initiative (n = 166). We also identified
samples in the Deciphering Developmental Disorders
(DDD) cohort, described below as we recalled the vari-
ants using our own analyses [39, 49, 62, 63]. In total, 51,
616 published individuals were screened. Cases had to
have a variant in an HNRNP to be included (i.e., not
solely changes in gene expression as seen in some neu-
rodegenerative phenotypes). Publications had to include
at least one of the disorders under the HPO terms “ab-
normality of the nervous system physiology” (HP:
0012638) and/or “abnormality of the nervous system
morphology” (HP:0012639). This includes, but is not
limited to, developmental delay/intellectual disability
(DD/ID), seizures, and behavioral abnormalities such as
autism spectrum disorder (ASD). Note that neurodegen-
erative phenotypes, such as ALS, were not included as
part of this analysis. Clinical information was requested
from authors when possible for larger sequencing stud-
ies. Duplicates were removed based on sample ID, shar-
ing of multiple variants, and disclosure of duplicates in
publications. When possible, samples were excluded if
Table 1 Gene families involved in RNA processing reaching FDR significance in Coe et al. [1] and their role in disease
Gene family Genes reaching FDR significance # of NDD candidate genes in gene family
Chromodomain DNA-binding proteins CHD2, CHD3, CHD4, CHD7, CHD8 6/10
BAF complex ARID1B, BCL11A, SMARCA2, SMARCA4, SMARCD1 16/24
Heterogeneous nuclear ribonuclear proteins HNRNPU, SYNCRIP, HNRNPD, HNRNPK 7/33
Lysine acetyltransferases CREBBP, DLG4, EP300, TAF1 5/17
Gene families were defined by the HUGO Gene Nomenclature Consortium. At least three members of the gene family must reach FDR significance to be included.
NDD candidate genes were determined by OMIM and a literature search. Coe et al. [1] n = 11,722 exomes
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Table 2 Previous disease associations for genetic variation in HNRNP genes
Gene Disorder Type of variation
HNRNPA1 ALS/FTL [8]
Multisystem proteinopathy [8, 9]
MIS
MIS
HNRNPA2/B1 ALS/FTLD [8, 9]
Multisystem proteinopathy [8, 9]
MIS
MIS
HNRNPA3 ALS/FTLD [8, 9]
Multisystem proteinopathy [8, 9]
MIS
MIS
HNRNPD/AUF1 4q21 microdeletion/duplication/triplication syndrome [10] CNVs
HNRNPH1 HNRNPH1-related syndromic ID [11] MIS20/small CNVs
HNRNPH2 Bain-type ID [12] MIS20




HNRNPR HNRNPR-related disorder [18] LGD/MIS20
SYNCRIP/HNRNPQ 6q proximal deletions [19] Chromosomal deletion
HNRNPP/FUS/TLS ALS/FTLD [3] LGD/MIS




MIS missense, MIS20 missense variants with CADD scores ≥ 20, indicating they are in the top 1% of likely pathogenic variants, CNVs copy number variants, LGD
likely gene disrupting, ALS amyotrophic lateral sclerosis, FTLD frontotemporal lobar degeneration, ID intellectual disability, AKS Au-Kline syndrome
Candidate NDD HNRNPs: HNRNPA0, HNRNPA1, HNRNPA2B1, HNRNPAB,  
HNRNPD, HNRNPF, HNRNPH1, HNRNPH2, HNRNPH3, HNRNPK, 
HNRNPLL, PTBP2, HNRNPR, SYNCRIP, HNRNPU, HNRNPUL1, HNRNPUL2
Identification of candidate NDD HNRNPs
CNV intersection
Genes included in known 
genomic disorders
n = 6 HNRNPs
Protein Homology
13 hnRNP homology groups
n = 5 HNRNPs highly homologous to 
known NDD genes
n = 117 probands with 
SNVs/indels in 16 HNRNPs
n = 11 probands with 
CNVs in 4 HNRNPs
Literature Search
Identification of novel probands with HNRNP variants
Novel probands
n = 118 probands with mutations in 17 HNRNPs
Genes Screened/Cohort
ASID Network: HNRNPF, HNRNPK, HNRNPR, SYNCRIP, HNRNPU, and HNRNPUL1
BGL: all HNRNPs except HNRNPH2 
SPARK: all HNRNPs
Databases/collaborations: all HNRNPs
Candidate NDD HNRNPs: HNRNPA0, HNRNPA3, HNRNPAB, 
HNRNPA2B1, HNRNPC, HNRNPC, HNRNPCL1, HNRNPCL4, RALY, RALYL,
HNRNPD, HNRNPDL, HNRNPF, HNRNPH1, HNRNPH2, HNRNPH3, 
HNRNPK, HNRNPLL, PTBP2, HNRNPR, SYNCRIP, HNRNPU, HNRNPUL1, HNRNPUL2
HNRNPs having  3 probands
Final candidate NDD HNRNPs: HNRNPAB, HNRNPD, HNRNPF, HNRNPH1, 
HNRNPH2, HNRNPH3, HNRNPK, HNRNPR, SYNCRIP, HNRNPU, 
HNRNPUL1, HNRNPUL2
Functional impacts of novel variation in HNRNPs




gnomAD (pLI, missense Z)
GeVIR (GEVIR, LOEUF, VIRLoF)






Disorder profiles and comparisions
Comparison to similar disorders by HPO terms 
Phenotypic Analyses
(n = 221 probands)
By gene





(n = 88 phenotypes)
Significantly enriched genes





n = 81 de novo variants
de novo enrichment 
analyses
Missense analyses 
Clustering of missense variants 
(CLUMP)
MetaDome
n = 86 missense variants
Mutational Analyses
n = 225 variants
Fig. 1 Study workflow. Candidate NDD HNRNPs were determined from the literature and publicly available information (such as amino acid
sequences) and from identification of probands in our novel cohorts. The candidate NDD HNRNPs were finalized by considering only genes in
which at least three probands were identified from published and/or novel sources. Functional impacts focused on these finalized NDD HNRNP
candidates and included pathogenicity predictions (gnomAD and GEVIR), de novo enrichment analyses (using the Chimpanzee–Human [CH]
model and denovolyzeR), missense analyses (using CLUMP and MetaDome), expression analyses of fetal cortex and adult tissues, and phenotypic
analyses within HNRNPs, across HNRNPs, and in comparison to other similarly presenting disorders by HPO terms. CNV: copy number variant; pLI:
loss-of-function intolerance; LGD: likely gene disrupting; NMD: nonsense mediated decay; HPO: human phenotype ontology
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they had a likely causative variant in an NDD can-
didate gene, as determined by multiple publica-
tions [1, 58].
Protein homology analysis to identify additional candidate
NDD HNRNPs
To determine if there were a subset of hnRNPs with
sequence similarity to known NDD hnRNPs, and thus
potential candidate NDD genes, we utilized protein
homology analysis (Fig. 2 and Additional File 2: Fig.
S1). Protein homology was determined using Clustal
Omega with canonical transcript sequences obtained
from UniProt and clustering was performed in R
(v.3.6.1) using the corrplot package (v.0.84) to identify
shared protein homology.
CNV intersection
In order to determine if any HNRNPs are dosage sensi-
tive, we intersected the HNRNPs with a list of 58 gen-
omic disorders based on previous CNV morbidity maps
and the DECIPHER database (Table 3) [10, 13, 19, 20,
64–67]. From this, we identified 15 probands with CNVs
spanning only an NDD HNRNP gene or neighboring
genes not predicted to be haploinsufficient.
Identification of novel probands with HNRNP variants
Probands were collected from multiple cohorts (n= 32,359
probands) (Additional File 1: Table S1). We also queried
ClinVar and DECIPHER databases. We identified 122 pro-
bands with SNVs, indels, or CNVs impacting 14 HNRNPs





















































































































































































































































































































































































































































































































































































































































































































































































Fig. 2 Protein similarity of hnRNPs. Correlation plot of hnRNPs by canonical amino acid sequence. Pearson correlation values are shown in the
bottom half of the plot and are shown visually on the top half of the plot
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Families where recontact was possible were invited to
participate in a remote comprehensive clinical workup
that included diagnostic evaluation, medical history, and
neuropsychological assessment. All experiments carried
out on these individuals were in accordance with the
ethical standards of the responsible committee on hu-
man experimentation (institutional and national), and
proper informed consent was obtained for sequencing,
recontact for inheritance testing, and phenotypic
workup. When physicians or families could not be con-
tacted, deidentified clinical information was used. Pro-
bands were excluded if they reportedly had (1) a
causative variant in another NDD-related gene, (2) a
known inherited variant in an HNRNP (other than mo-
saic), (3) a variant observed in gnomAD, (4) a missense
variant with a CADD (v1.6, GRCh38) score < 20, (5) con-
sanguineous parents (which was based on clinical his-
tory), and/or were (6) born prematurely (prior to 37
weeks), or (7) too young to assess for DD (< 1 year).
However, individuals excluded for our HNRNPs cohort
were still considered in the total number of individuals
for statistical analyses. For probands from large sequen-
cing studies, these criteria were not always available;
therefore, a small number of those not meeting our cri-
teria may be included due to limited information.
Cohorts
ASID Network
For our Autism Spectrum/Intellectual Disability (ASID)
network (n = 16,294 individuals), six HNRNPs were pre-
viously assessed using targeted sequencing with single-
molecule molecular inversion probes: HNRNPF,
HNRNPK, HNRNPR, SYNCRIP, HNRNPU, and HNRN
PUL1, as described by Stessman et al., identifying 14
probands (seven with DNVs) included in the current
study [34, 68]. All variants were validated using Sanger
Table 3 Genomic disorders spanning NDD HNRNPs
Genomic
disorder










Yes DD/ID, seizures, structural brain abnormalities, speech delay
9q21.32 deletions HNRNPK Yes DD/ID, motor delay, speech delay, structural brain abnormalities, hypotonia, skeletal










No DD/ID, emotional/behavioral issues, speech delay
1p36 monosomy HNRN
PR
No DD/ID, skeletal abnormalities, genitourinary issues, seizures, structural brain
abnormalities
CNV copy number variant, DD/ID developmental delay/intellectual disability, ASD autism spectrum disorder
Fig. 3 Pathogenicity assessment of variation in hnRNPs. pLI and Z-
scores were obtained from gnomAD. pLI scores are significantly
higher among NDD hnRNPs (n = 12) compared to non-NDD hnRNPs
(n = 20), suggesting LGD variants are more likely to be damaging. Z-
scores trend towards being significantly higher for NDD hnRNPs,
suggesting severe missense variants are likely to be damaging. T-test
with Welch’s correction. *p < 0.05. pLI: loss-of-function intolerance
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sequencing, although not all had parental DNA available
for inheritance testing. Information for a subset of these
probands are available in denovo-db v1.6.
BGL
From Baylor Genetics Laboratory (BGL; n = 9536, in-
cluding 1744 trios), 34 novel probands are included in
the current study (four with DNVs) and four previously
published probands with DNVs (for a total of 38 pro-
bands) [23]. These probands are all from clinical exome
sequencing samples broken down into “neurologic” phe-
notypes (n = 2364, including 429 trios; developmental
delay [DD]/intellectual disability [ID], speech delay, and
autism spectrum disorder [ASD]) and “neurologic plus
other organ systems” (n = 7172, including 1315 trios).
Exome sequencing was performed as described previ-
ously, and DNVs were validated by Sanger sequencing
[69]. All HNRNPs were queried in the BGL data except
HNRNPH2. Phenotypic information was obtained from
BGL clinical indications for sequencing and/or from
reporting physicians when available.
SPARK Consortium
From the SPARK Consortium, with individuals ascer-
tained for ASD diagnoses, nine probands with DNVs are
included in the current study, as well as an additional
published proband (for a total of 10 probands) [42]. Pro-
bands identified by the SPARK Consortium were se-
quenced as previously described [42]. SPARK
Consortium probands were used in all statistical ana-
lyses, although complete phenotypic information was
not always available.
Deciphering Developmental Disorders (DDD13K)
Data for 9860 trios from the DDD cohort were obtained
and reanalyzed [62]. We applied FreeBayes (version
v1.1.0–3-g961e5f3) and GATK (version 3.7) for SNV/
indel calling independently in 9308 DDD families where
both parents were available (with 28,476 samples includ-
ing 9860 probands) [70, 71]. BCFtools (version 1.3.1)
was used for left-align and normalization post calling
[72]. For quality control, we filtered for read depth (DP >
9) for all family members and filtered allele balance (AB
> 0.25) and PHRED genotype quality (GQ > 20) filters in
probands. Candidate de novo SNVs/indels were only ob-
served in probands but not in parents and were required
to be identified by both FreeBayes and GATK. Variants
were then annotated using CADD (v1.6, GRCh38).
International collaborations
GeneMatcher and GeneDx were utilized to identify 24
individuals, 21 of whom have DNVs [73]. GeneMatcher
requests were made for each HNRNP identified in an
NDD cluster (Fig. 2). Probands were sequenced at
varying locations, including several by GeneDx, whose
protocol was described previously. Deidentified clinical
information was obtained from physicians or families
were invited for remote clinical workup. These probands
were not used in de novo statistical calculations but
were considered among phenotypic analyses.
Four probands with DNVs were obtained from the
Radboud University Medical Center (RUMC) in the
Netherlands. These probands were not used in de novo
statistical calculations but were considered among
phenotypic analyses.
Databases
Large databases were also used to identify novel pro-
bands. Each hnRNP-encoding gene was queried in
MyGene2 (https://mygene2.org/MyGene2/), a database
generated by the University of Washington Center for
Mendelian Genomics, identifying two probands (one
proband was identified via both MyGene2 and Gene-
Matcher) [74]. MyGene2 probands were not used for de
novo statistical calculations but were considered for
phenotypic analyses.
DECIPHER (n > 33,000 individuals; https://decipher.
sanger.ac.uk/) and ClinVar (n = 874,088; https://www-
ncbi-nlm-nih-gov.offcampus.lib.washington.edu/clinvar/)
were queried and only those with phenotypic informa-
tion available were included in this study, adding 12 (10
with DNVs) and 19 (seven with DNVs) new probands,
respectively. Probands were considered novel if they had
not been previously published. DECIPHER and ClinVar
probands were included in phenotypic analyses but not
de novo statistics.
Functional impacts of novel variation in HNRNP genes
Pathogenicity predictions, de novo enrichment, and
missense analyses
To further characterize the types of variation among
NDD HNRNPs, we compared the probability of patho-
genicity of LGD and missense variants using gnomAD
(loss-of-function intolerance [pLI] and missense Z-
scores; https://gnomad.broadinstitute.org/) and Gene
Variation Intolerance Ranking (GeVIR; http://www.
gevirank.org/) scores and percentiles, which include
loss-of-function observed/expected upper bound fraction
(LOEUF) metrics, of NDD HNRNPs to non-NDD
HNRNPs using a one-way t-test in GraphPad Prism
(v.8.3.0) (Fig. 3 and Additional File 2: Fig. S3, Additional
File 1: Table S2) [75].
For de novo enrichment analyses, 33,688 probands
with trio sequencing (n = 36,460 for HNRNPH2 and n =
36,814 for HNRNPU) were used (Additional File 1: Table
S6). Only studies with a clear sample size were used to
estimate de novo burden (i.e., n > 1, cohort total sizes in-
cluded in publication). Only genes determined as NDD
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HNRNPs were analyzed. In total, 78 HNRNP variants
were analyzed (Additional File 1: Table S7). Two models,
the chimpanzee–human divergence (CH) model and
denovolyzeR, were used to assess the excess of de novo
LGD and missense variants as previously described
(Fig. 4a) [1, 34, 76, 77]. Briefly, the CH model utilizes
locus-specific transition/transversion/indel rates and
chimpanzee–human coding sequence divergences to es-
timate the expected number of de novo mutations, while
the denovolyzeR utilizes trinucleotide context, exome
depth, and divergence between macaque and human
over a ± 1 megabase-pair window and includes known
mutational biases like CpG hotspots. Each model was
corrected for the number of genes included in the model
(n = 18,946 for the CH model and n = 19,618 for denovo-
lyzeR) as well as three mutation-type tests per gene and
two tests per mutation type (FWER for CH model: q <
4.4 × 10− 7, FWER for denovolyzeR q < 4.24 × 10− 7).
Missense variants were analyzed using two methods:
CLUMP (CLUstering by Mutation Position) analysis and
MetaDome assessment [78–80]. Only genes determined
NDD HNRNPs were analyzed. CLUMP assesses the clus-
tering of missense mutations and was performed as pre-
viously described, but here using the gnomAD non-
neuropsychiatric group as controls (gnomAD n = 114,
704; 1958 missense variants; current cohort missense
n = 80 variants) (Fig. 4b, Additional File 1:Table S6) [80].
All calculations were performed using R (v.4.0.0) or py-
thon (v.3.7.7). Missense variants were also assessed for
clustering by phenotype. Mutations were queried in
MetaDome to assess for protein domain disruptions
(Fig. 5) [78]. LGD variants were also assessed for suscep-
tibility to nonsense mediated decay (NMD) using
NMDEscPredictor (https://nmdprediction.shinyapps.io/
nmdescpredictor/) and splicing impact using MaxEntS-
can (Fig. 5, Additional File 1: Table S7) [81, 82].
GTEx and single-cell expression analyses
Transcript-level expression from adult tissues obtained
from GTEx (https://gtexportal.org/) for each gene was
compared using t-tests between NDD and non-NDD























































































































































Fig. 4 De novo enrichment and clustering of missense variation analyses of NDD hnRNPs. a De novo variation was assessed for NDD HNRNPs
using two statistical models: the CH model and denovolyzeR. Right/above the dotted line indicates the gene achieves exome-wide significance
(q < 4.24 × 10− 7) while right/above the dashed line indicates the gene reaches nominal significance (q < 0.05). HNRNPU reaches exome-wide
significance for all protein-impacting variants (Protein) and LGD variants, with severe missense variants reaching significance by only the CH
model. SYNCRIP reaches exome-wide significance for LGD variants and all protein-impacting variants by the CH model alone. HNRNPD reaches
nominal significance by the CH model. P values are FDR corrected with the number of genes (n = 18,946 for CH model and n = 19,618 for
denovolyzeR) with three tests per gene (LGD, missense, and all protein changes) and two tests (CH model and denovolyzeR) per mutation type.
Only cohorts with known de novo status were included, as listed in Tables S1 and S7. Statistics can be seen in Table S6. b Analysis of clustered
missense variants. Clustering of missense variants was analyzed using CLUMP; scores are shown in Table S6 (paired t-test). Compared to the non-
neuropsychiatric subset of gnomAD (n = 114,704, 1958 missense variants), the CLUMP score for NDD hnRNPs (red) among probands is
significantly lower than controls in gnomAD (black), indicating more clustering of mutations (shown by arrow). Note that only genes with variants
in the current cohort could undergo this analysis. hnRNPH2, hnRNPK, hnRNPR, and hnRNPUL1 each have independent significant clumping
compared to gnomAD controls. c CLUMP scores for missense variants in probands with ASD (n = 60). HnRNPH2, hnRNPK, hnRNPR, and
hnRNPUL1 reach significance independently. *p < 0.05, **p < 0.01, ***p < 0.001. LGD: likely gene disrupting; Missense: severe missense (CADD
≥ 20); Protein: all protein-affecting variants
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between individual genes (Fig. 6a, Additional File 2: Figs.
S3C,D, Additional File 1: Table S3). We used previously
described single-cell RNA (scRNA) sequencing data
generated from 48 individuals to assess gene ex-
pression during fetal human cortical development,
which is available from the UCSC cell browser:
https://cells.ucsc.edu/ [84]. To determine cell en-
richment, data were tested using a Wilcoxon ranked
sum test followed by Bonferroni correction in R, as
previously described [84]. Student t tests and two-
way ANOVA among all HNRNPs, between NDD
and non-NDD HNRNPs, or HNRNPs and genes
associated with similarly presenting disorders deter-
mined the difference in fold-enrichment using
GraphPad Prism (Figs. 6b,c and 8b,c, Additional
File 2: Figs. S3A,B, Additional File 1: Tables S4–5).
Correlations among scRNA sequencing data were
performed in R (v.3.6.1) using the corrplot package
(v.0.84). One-way t-tests were performed between
each NDD HNRNP group (as in Fig. 2) using
GraphPad Prism. HNRNPs were also entered into
Specific Expression Analyses (SEA) to determine
enrichment of expression across brain regions
(Fig. 6d) [85]. Expression among these tissues was
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Fig. 5 hnRNP proband variants. Protein structure, known binding motif, number of probands by mutation type, location of variants in each
protein, and known associated disorders of NDD hnRNPs are shown. Novel cases are above the protein with published cases below. Red
indicates LGD variants and blue represents severe missense variants. RRM: RNA recognition motif; qRRM: quasi-RNA recognition motif; KH: K-
homology domain; RGG: Arginine-glycine rich (RGG) box; NLS: nuclear localization sequence. Further details of each variant are shown in Table
S7. Adapted from Geuens et al. [83]. a Gene reaches exome-wide significance for all protein-impacting variants by CH model. b Gene reaches
exome-wide significance for all protein-impacting variants and LGD variants by CH model. c Gene reaches exome-wide significance for all
protein-impacting variants and LGD variants by CH model and denovolyzeR. d Gene reaches significance for missense variant clustering
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compared using Fisher’s exact tests and followed by
Benjamini-Hochberg correction.
Phenotypic analyses
Phenotypes were defined by Human Phenotype Ontol-
ogy (HPO) terms when possible. Those that occurred in
≥ 20% of probands in at least one HNRNP cohort were
considered characteristic for the disorder and used for
statistical analyses. Traits occurring less than that were
considered not likely to be syndromic. This resulted in a
total of 88 phenotypes. For quantitative measures (e.g.,
head circumference), qualitative terms were used if pro-
vided by a clinician (e.g., microcephalic) or determined
based on top/bottom 3rd percentile.
Phenotypic information was compared across
HNRNP cohorts using RVAideMemoire (version 0.9–
73) pairwise Fisher’s exact tests with Bonferroni cor-
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Amygdala Cerebellum Cortex Hippocampus Striatum Thalamusd
Fig. 6 HNRNP expression in adult and developing fetal cortex tissues. a Heatmap showing transcript-level expression values for NDD hnRNPs for
adult brain tissues in GTEx. All tissues are shown in Fig. S4, and p values among individual HNRNPs are shown in Table S3. b Heatmap showing
fold change of expression of each NDD HNRNP among 48 different cell types in the developing fetal cortex. Blue indicates increase in fold
change of expression and red indicates decreased expression, as determined by Z-scores. NDD HNRNPs have higher fold expression change in
MGE progenitors, radial glia, and excitatory neurons, while depleted in inhibitory neurons. All HNRNPs are shown in Fig. S3. Significance indicates
enrichment in particular cell types by Wilcoxon ranked sum test with Bonferroni correction based on number of cell types. P values and fold
change for scRNA data from developing human cortex can be seen in Tables S4 and S5. c Correlation plot of developing fetal cortex gene
expression. Pearson correlation R values are shown in the bottom half of the plot, which are visually in the top half of the plot. P values were
corrected by number of genes [23] and number of cell types [48]. HNRNPs in the same homology group tend to have more correlated
expression. d Specific brain region enrichment as determined by SEA, showing enrichment of expression of the NDD HNRNPs in the early fetal
striatum and early-mid fetal amygdala. *p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001
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NDD HNRNPs, n = 9 for LGD NDD HNRNPs, n = 10
for missense NDD HNRNPs), number of phenotypes
(n = 88), and number of mutation categories (n = 3: all
mutations, LGD, and missense) tested, as well as
across mutation types (LGD vs. missense) within
HNRNP cohorts using Fisher’s exact tests (Fig. 7,
Additional File 1: Tables S8–9). All calculations were
performed using GraphPad Prism or R. Phenotypes
were compared to other known disorders by charac-
teristic HPO terms using PhenPath (http://phenpath.
biocomp.unibo.it/phenpath/), which returns disorders
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Fig. 7 Phenotypic information of 189–221 hnRNP-variation probands. a Correlation matrix of phenotypes across hnRNP probands. Genes are in
order of protein similarity as determined by Clustal Omega and canonical protein sequences as in Fig. 1. Phenotypes correlate across all HNRNPs,
except HNRNPF due to sample size. Size and shade of circle represent correlation coefficients, which are shown on bottom half of matrix.
Correlations for LGD and missense variants separately are in Fig. S4. P values, which are corrected by number of genes [23] and phenotypes (88,
occurring in at least 20% of any HNRNP group) can be seen in Table S9. b Plot comparing protein and phenotype correlations that are over
Pearson’s R = 0.5. Colors are the same as in Fig. 2 protein groups. Those with more similar protein sequences tend to be more phenotypically
similar. c Plot of phenotypes of all probands by mutation type. Individual HNRNPs can be seen in Fig. S5. d Heatmap indicating percent of
probands with phenotype. Sample sizes can be seen in Table S7 and range from n = 2 (HNRNPF) to n = 83 (HNRNPU). Lines indicate significant
differences as determined by pairwise Fisher’s exact tests with Bonferroni correction based on 12 genes, 88 phenotypes, and three mutational
categories. Red dashed lines indicate significance with only LGD variants. Raw p values can be seen in Tables S8. *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001. LGD: likely gene disrupting; MIS: severe missense (CADD ≥ 20)
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Results
Twelve HNRNPs are NDD candidates based on literature
search, protein homology, CNV intersection, and
identification of new probands
In order to identify NDD candidate HNRNPs, we initially
considered cases with DNVs in the literature. This re-
sulted in 16 genes with at least one published case as po-
tential NDD candidate genes: HNRNPA0, HNRNPA3,
HNRNPAB, HNRNPA2B1, HNRNPC, HNRNPD, HNRN
PF, HNRNPH1, HNRNPH2, PTBP2, HNRNPK, HNRN
PLL, SYNCRIP, HNRNPR, HNRNPU, and HNRNPUL1
(n = 117 probands; Fig. 1, Additional File 1: Tables S1,
S7, S8, and S11).
To identify other genes in the family that may not
have published cases, we considered the extent of shared
protein homology among hnRNPs (Fig. 2 and Additional
File 2: Fig. S1). Among 23 core hnRNPs and 10 minor
hnRNPs, we distinguished 13 protein groups based on
protein homology clustering: (1) FUS (Fused in sarcoma,
also known as hnRNPP), (2) hnRNPD-related proteins,
(3) hnRNPA-related proteins, (4) hnRNPR/SYNCRIP, (5)
hnRNPM, (6) RMBX (RNA-binding motif protein X-
linked, also known as hnRNPG)-related proteins, (7)
hnRNPH/F-related proteins, (8) hnRNPU-related pro-
teins, (9) PTBP (also known as hnRNPI)-related pro-
teins, (10) hnRNPL-related proteins, (11) hnRNPC-
related proteins, (12) hnRNPK, and (13) PCBP (also
known as hnRNPE)-related proteins. From this, we iden-
tified seven additional hnRNPs that, while they do not
have published cases with NDDs, cluster with our other
candidate hnRNPs: hnRNPCL1, hnRNPCL4, RALY,
RALYL, hnRNPH3, hnRNPDL, and hnRNPUL2.
We determined if any HNRNPs are dosage sensitive by inter-
secting the HNRNPs with a list of 58 genomic disorders based
on previous CNV morbidity maps and the DECIPHER data-
base (Table 3) [10, 13, 19, 20, 64–67]. Of the 33 HNRNPs, six
are in regions of known genomic CNV disorders: HNRNPD,
HNRNPH1, HNRNPK, HNRNPR, SYNCRIP, and HNRNPU,
further supporting their likely role in NDDs. This analysis did
not identify any new candidate NDD HNRNPs but did provide
additional evidence for their roles in NDD pathogenicity.
Genes were also considered as candidate NDD
HNRNPs if we identified variants in our novel cohorts.
This resulted in 17 genes with at least one novel case as
potential NDD candidate genes: HNRNPA0, HNRNPA1,
HNRNPA2B1, HNRNPAB, HNRNPD, HNRNPF, HNRN
PH1, HNRNPH2, HNRNPH3, HNRNPK, HNRNPLL,
PTBP2, SYNCRIP, HNRNPR, HNRNPU, HNRNPUL1,
and HNRNPUL2 (n = 118 probands; Fig. 1, Additional
File 1: Tables S1, S7, S8, and S11).
Finally, NDD HNRNPs were finalizing by identification
of at least three probands in our combined literature and
novel cohorts. This resulted in the following being consid-
ered NDD HNRNPs: HNRNPAB, HNRNPD, HNRNPF,
HNRNPH1, HNRNPH2, HNRNPH3, HNRNPK, HNRNPR,
SYNCRIP, HNRNPU, HNRNPUL1, and HNRNPUL2.
NDD HNRNPs are more sensitive to mutation than non-
NDD HNRNPs
We considered each gene’s tolerance to mutation by
assessing gnomAD metrics pLI and missense Z-scores as
well as GeVIR scores (Fig. 3 and Additional File 2: Fig.
S2, Additional File 1: Table S2) [75, 87]. As a group, pLI
scores are significantly higher among NDD HNRNPs
compared to non-NDD HNRNPs (p = 0.03, one-way Stu-
dent’s t test). Similarly, NDD HNRNPs’ missense Z-
scores trend higher than non-NDD HNRNPs; GeVIR
scores show the same pattern. Specifically, NDD
HNRNPs have significantly higher LOEUF autosomal
dominant scores (p = 0.03, one-way Student’s t test) and
Variation Intolerant Region Loss-of-Function (VIRLoF)
scores, which takes both missense and LGD variants into
account (p = 0.04, one-way Student’s t test). GeVIR auto-
somal recessive scores show a similar pattern for LOEUF
scores (p = 0.04, one-way Student’s t test), but as all of
our variants are heterozygous, this information was not
utilized in our study. This suggests that LGD and severe
missense variants are more likely to be damaging among
NDD HNRNPs compared to the non-NDD HNRNP fam-
ily members.
Enrichment of de novo HNRNP variants
In total, 225 probands with SNVs or indels in NDD
HNRNPs were identified from 83,975 individuals. Inher-
itance was determined for 73.8% of NDD HNRNP SNV
and indel variants (Table 4, Fig. 3, and Additional File 1:
Table S7). Of variants with known inheritance, DNVs
account for 98.8% of variants, with one mosaic variant
inherited from the unaffected father, who also carries
the variant mosaically (Proband 124, HNRNPU proband
1) [26]. LGD variants represent 61.8% (n = 139/225 vari-
ants, inheritance known for 82.7%; 99.1% de novo) of the
NDD HNRNP cohort, while severe missense variants
(MIS20: CADD score ≥ 20, being in the top 1% of pre-
dicted pathogenic mutations and MIS30: CADD ≥ 30
top 0.1% of predicted pathogenic variants) account for
38.2% of variants (n = 86/225 variants, inheritance
known for 59.3%; 98% de novo; MIS20, MIS30, and
those without CADD scores available were included).
Twelve of the 16 small CNVs have known inheritance
status, and all are de novo (Additional File 1: Table S12).
In order to identify genes with a significant excess of
DNVs, we examined 41,779 parent–child trios from 13,
437 families with DD/ID, 20,542 families with ASD,
1421 families with epilepsy, and 6379 families from clin-
ical exome testing. We applied two statistical models,
denovolyzeR and the CH model, to genes that had
DNVs from cohorts with known sample size (n = 78
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variants, Fig. 4a, Additional File 1: Table S6) [76, 77].
We find that only HNRNPU achieves exome-wide sig-
nificance (p < 4.24 × 10− 7) for de novo LGD and all
protein-impacting variants by both models. SYNCRIP,
for all protein-impacting variants and LGD variants,
reaches exome-wide significance only by the CH model,
while all protein-impacting variants of HNRNPD reach
nominal significance (p < 0.05) by the CH model. Only
HNRNPU reaches exome-wide significance for an excess
of severe de novo missense variation after multiple test-
ing correction (FWER, p < 4.24 × 10− 7), and only by the
CH model. Based on these DNV models, only HNRNPU,
SYNCRIP, and HNRNPD reach significance for increased
number of variants than one would expect.
Missense mutation analyses
As pathogenic missense variants are known to cluster
for some proteins, such as hnRNPH2 in the M9 nuclear
targeting signal, we assessed whether there was any add-
itional evidence of missense variant clustering across
hnRNPs [12]. We examined all MIS20 and MIS30 vari-
ants in our cohort (n = 80) and compared them to the
non-neuropsychiatric subset in gnomAD using CLUMP
(n = 1958) (Fig. 4b, Additional File 1: Table S6) [80]. In
order to control for platform differences, variants were
only included if exon coverage was at least 20-fold in
gnomAD (the first two exons of HNRNPUL1 were ex-
cluded). The CLUMP scores for NDD hnRNP missense
variants are significantly lower than those of controls
from gnomAD (p = 0.03, paired t-test) suggesting clus-
tering of variants. hnRNPH2, hnRNPK, hnRNPR, and
hnRNPUL1 independently have significantly more clus-
tering of missense variants than controls (p < 0.05 for
hnRNPK and hnRNPUL1, p < 0.01 for hnRNPH2 and
hnRNPR). Thus, for multiple hnRNPs, clustering of mis-
sense variants likely contributes to pathogenicity, poten-
tially impacting particular protein domains. Notably, this
clustering was more significant among particular pheno-
types, including ASD (p = 0.005, HNRNPR alone p =
0.007). In hnRNPH2, missense variants cluster signifi-
cantly among probands with growth delay (p = 0.01),
motor delay (p = 0.001), speech delay (p = 0.006), micro-
cephaly (p = 0.01), hypotonia (0.003), seizures (p = 0.01),
and cardiac abnormalities (p = 0.02) compared to con-
trols. Cardiac abnormalities also have a clustering of
missense variants among HNRNPK probands (p = 0.004).
Variants cluster among probands with hypospadias, joint
hypermobility, and scoliosis among HNRNPH1 probands
(p = 0.04 for each). In addition to ASD, variants in pro-
bands with speech delay or microcephaly and HNRNPR
variants are clustered (p = 0.005 and p = 0.001, respect-
ively). We also applied MetaDome to identify such do-
mains and as another predictor of pathogenicity. There
was no significant difference between variants in known
domains and unknown domains. Other than the M9 nu-
clear localization signal, there was clustering of missense
variants in the RNA-binding domain of hnRNPH2. In
hnRNPK, 70% of missense variants (n = 7/10) cluster in
the KH domains, which are important in RNA binding
and recognition. Almost half (42.9%, n = 3/7) of missense
variants in SYNCRIP cluster in its RNA recognition
motif while de novo missense mutations in hnRNPU
cluster in the SPRY domain and AAA domain (n = 3/16
each). Twenty-five percent (2/8) of missense variants in
hnRNPUL1 occur in the SAP domain, important for
RNA and DNA binding. Thus, RNA recognition and
binding are likely responsible for many of the missense
variants observed in the hnRNPs.
HNRNP brain expression analyses
In order to understand the pathogenesis of variation in
HNRNPs, we explored the expression of the genes in
both adult tissues and the developing human cerebral
cortex [84]. GTEx analysis of adult tissues shows that
the HNRNPs as a whole (n = 33) are expressed across all
brain regions, as well as ubiquitously across tissues, with
the exception of HNRNPCL1, RALYL (HNRNPCL3),
HNRNPCL4, and RBMXL2, which broadly show low
levels of expression (Fig. 6a and Additional File 2: Figs.
S3C,D). Significant changes in expression are seen based
on individual genes and by tissue type (p < 0.0001 for
both by two-way ANOVA), with highest expression
Table 4 Inheritance of 225 SNVs and indels in NDD HNRNPs
Variant type De novo % of variant type
(n)
Inherited % of variant type
(n)
Unknown % of variant type
(n)
Total % of all variants
(n)
LGD 82 (114/139) 0.7 (1/139) 17.3 (24/139) 61.8 (139/225)
All MIS 58.1 (50/86) 1.2 (1/86) 40.7 (35/86) 38.2 (86/225)
MIS—no CADD
score
50 (4/8) 0 (0/8) 50 (4/8) 3.6 (8/225)
MIS20 57.5 (42/73) 1.4 (1/73) 41.1 (30/73) 32.4 (73/225)
MIS30 80 (4/5) 0 (0/5) 28.6 (2/5) 2.7 (6/225)
All variants 73.2 (164/225) 0.9 (2/225) 25.3 (56/225) 100 (225/225)
LGD likely gene disruptive, MIS missense, MIS20 CADD score ≥ 20, MIS30 CADD score ≥ 30. NDD HNRNPs include HNRNPAB, HNRNPD, HNRNPF, HNRNPH1, HNRNPH2,
HNRNPH3, HNRNPK, SYNCRIP, HNRNPR, HNRNPU, HNRNPUL1, and HNRNPUL2. Variants identified in non-NDD HNRNPs are in Table S7
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levels in the brain seen typically in the cerebellum. Be-
tween NDD and non-NDD HNRNPs, no significant dif-
ferences are observed (Additional File 2: Fig. S3). The
general high expression of these genes may contribute to
phenotypes observed.
scRNA sequencing from the developing cortex con-
firms widespread expression across brain cells, especially
neuronal and neuronal progenitor cell types, suggesting
that these genes could play a role in neuronal differenti-
ation (Fig. 5b and Additional File 2: Figs. S4C,D) [84].
We find that HNRNP expression is enriched among ra-
dial glia, which act as neural stem cells, but decreased
among immature inhibitory and excitatory neurons, al-
though it does vary by HNRNP (p < 0.05 to p < 0.0001,
Wilcoxon ranked sum test, Bonferroni correction; Fig. 6a
and Additional File 2: S3C, Additional File 1: Table S4).
While significant differences are seen by two-way
ANOVA between individual HNRNPs, particularly for
PCBP1 (HNRNPI) and HNRNPCL3/RALYL, no signifi-
cant differences are observed between all NDD and non-
NDD HNRNPs (Additional File 2: Figs. S3A,B, Add-
itional File 1: Table S5). It is plausible that there are dif-
ferences between NDD and non-NDD HNRNP
expression that contribute to the development of NDD
phenotypes when perturbed.
Specifically, NDD HNRNPs are consistently signifi-
cantly enriched among dividing radial glia in G2/M
phase (all but HNRNPH1; p < 0.05 to p < 0.0001, Wil-
coxon ranked sum test, Bonferroni correction), dividing
radial glial cells during S phase (HNRNPK, HNRNPUL1,
HNRNPH3, HNRNPF, HNRNPH2, HNRNPR, HNRN
PAB, and HNRNPD; p < 0.05 to p < 0.0001, Wilcoxon
ranked sum test, Bonferroni correction), and in the med-
ial ganglionic eminences (MGE), which give rise to
major populations of inhibitory neurons of the cortex
(HNRNPUL2, HNRNPUL1, HNRNPU, HNRNPH3,
HNRNPF, HNRNPH1, HNRNPR, and HNRNPD, p < 0.05
to p < 0.0001, Wilcoxon ranked sum test, Bonferroni
correction), while depleted in newborn neurons in the
MGE (HNRNPUL1, HNRNPH3, HNRNPF, HNRNPH2,
HNRNPH1, HNRNPR, SYNCRIP, and HNRNPD; p < 0.05
to p < 0.0001, Wilcoxon ranked sum test, Bonferroni
correction) and newborn excitatory neurons (HNRNPK,
HNRNPUL1, HNRNPF, HNRNPH1, HNRNPR, HNRN
PAB, and HNRNPD; p < 0.05 to p < 0.0001, Wilcoxon
ranked sum test, Bonferroni correction). Among individ-
ual NDD HNRNPs, no significant differences are ob-
served by two-way ANOVA for the contribution of each
gene, highlighting their shared expression.
Hierarchical clustering shows that gene expression in
the developing cortex is highly correlated among specific
HNRNPs. Strong positive correlations are seen between
HNRNPD and HNRNPH3 (Pearson’s R = 0.87, p = 1.9e
−15), HNRNPU (Pearson’s R = 0.86, p = 3e−15), HNRN
PR (Pearson’s R = 0.83, p = 1.4e−13), and HNRNPK ex-
pression patterns (Pearson’s R = 0.8, p = 6.1e−12), HNRN
PR and HNRNPK expression patterns (Pearson’s R =
0.83, p = 2.7e−08), HNRNPUL1 and HNRNPH3 expres-
sion patterns (Pearson’s R = 0.82, p = 9.5e−13), HNRNPU
and HNRNPH3 expression patterns (Pearson’s R = 0.83,
p = 4e−13), and HNRNPH3 and HNRNPR (Pearson’s
R = 0.83, p = 4.1e−13) and SYNCRIP expression patterns
(Pearson’s R = 0.83, p = 1.8e−13). While there are posi-
tive correlations between almost all NDD HNRNP gene
expression patterns, the differences in expression along
with protein homology likely play a role in the pheno-
types observed.
Finally, we assessed the NDD HNRNP expression
among specific brain regions during development
(Fig. 5d). Expression is enriched in the striatum in early
fetal development (p = 0.002, Fisher’s exact test,
Benjamini-Hochberg correction) and the amygdala (p =
2.6e−4, Fisher’s exact test, Benjamini-Hochberg correc-
tion) during early-mid fetal development. HNRNPK,
HNRNPR, SYNCRIP, HNRNPF, and HNRNPU are
expressed in the striatum while HNRNPH1, HNRNPAB,
HNRNPUL1, HNRNPH3, and HNRNPU are expressed in
the amygdala. Expression among the striatum and amyg-
dala is likely impacted by variation in these genes, con-
tributing to probands’ phenotypes.
Phenotypic assessment of probands with HNRNP variation
The pathogenesis of variation in the HNRNPs, and most
genes in NDDs, has previously been discussed as inde-
pendent syndromes, as opposed to a spectrum of related
syndromes. While there are distinctions between the 12
HNRNPs and their related phenotypes, there is also con-
siderable overlap, which is expected due to the known
shared targets and functionality of hnRNPs [88]. Here,
we examine the phenotypic similarities and differences
among probands with variation in NDD HNRNPs (Fig. 7
and Additional File 2: Figs. S4 and S5, Additional File 1:
Table S7).
Our findings support the five reported disorders asso-
ciated with HNRNPs—Au-Kline syndrome (AKS,
HNRNPK), Bain-type ID (HNRNPH2), HNRNPH1-re-
lated syndromic ID, HNRNPR-related syndrome, and
HNRNPU-related disorder—and we propose seven new
disorders [12–18, 21–23, 25–27, 30].
Phenotypic comparisons and description
Overall, the phenotypes across the HNRNP-related disor-
ders are significantly highly correlated (p > 0.05 for all
pairs of HNRNPs except for HNRNPF likely due to small
sample size; Fig. 7a). These correlations are observed
when considering mutation type as well (Additional File 2:
Fig. S4), which is more critical for missense variation as
phenotypes could be due to a variety of molecular
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changes. Furthermore, this correlation is in line with the
degree of protein homology, with those being more simi-
lar at a protein level also being more alike at the pheno-
typic level (Fig. 7b). We caution that ascertainment bias
likely contributes to some of this, as the majority of our
cohorts have DD/ID and/or ASD, and the availability of
phenotypic information varies by gene and clinical refer-
ring center.
Neurobehavioral phenotypes have the most overlap
among HNRNP genetic disorders (Fig. 7c, d, Additional
File 1: Table S7). As expected, the most common pheno-
type among probands in our cohort is DD/ID (88.9%, n =
192/216, 12/12 disorders). DD/ID varies among disorders,
with diagnoses ranging from 44.4 to 100% of probands
but occurs at similar rates among LGD and missense pro-
bands (Additional File 2: Fig. S5). Delayed speech and lan-
guage development (57.9%, n = 114/197, 11/12 disorders)
is common among all HNRNP genetic disorders except
HNRNPF-related disorder, again with similar frequency
among both mutation types. Probands with Bain-type ID
(HNRNPH2) tend to have regression more often than
other HNRNP-related disorders (34.8%, n = 8/23). Seizures
are reported in 45.6% of probands (n = 98/215, 10/12 dis-
orders) with variation in HNRNPs, primarily driven by
probands with HNRNPU-related disorder (83.1%, n = 69/
83), who also have a significantly higher prevalence of sei-
zures compared to other HNRNP-related disorders (p =
0.009 compared to HNRNPD probands, p = 0.009 com-
pared to HNRNPH2 probands, p = 1.89e−10 compared to
HNRNPK probands, p = 0.002 compared to SYNCRIP pro-
bands; Fig. 7d, Additional File 1: Table S8). Seizures over-
all are more common among LGD probands, but only
with the inclusion of HNRNPU and HNRNPR probands
(OR = 2.7, 95% CI 1.5–5.2, Fisher’s exact test).
A range of brain imaging abnormalities are observed
among 37% (n = 70/189) of probands, with abnormalities
of the corpus callosum (particularly for HNRNPR pro-
bands) and cerebellar vermis hypoplasia (particularly
among HNRNPH1, HNRNPH2, and HNRNPR probands,
although not significantly) being most common. Behav-
ioral diagnoses, including ASD (35.6%, n = 73/205, 10/12
disorders), ADHD (8.7%, n = 17/195, 6/12 disorders),
among others, are shared across disorders. While not
significantly different, ASD is more common among
probands with variation in HNRNPD (46.2%, n = 6/13),
HNRNPF (100%, n = 3), HNRNPR (44.4%, n = 4/9), SYNC
RIP (57.7%, n = 15/26), and HNRNPUL2 (66.7%, n = 4/6),
while ADHD is prevalent among HNRNPR probands
(44.4%, n = 4/9) and aggression is common among
HNRNPD probands (33.3%, n = 4/12). HNRNPU-related
disorder probands with LGD variants also exhibit stereo-
typy (21.7%, n = 15/69, mostly recurrent hand flapping),
as do HNRNPR-related disorder probands (33.3%, n = 3/
9). Abnormal movements (22.2%, n = 44/198) are
reported in a subset of HNRNP genetic disorders, in-
cluding abnormal gait among probands with SYNCRIP-
related disorder (20%, n = 5/25), dystonia for probands
with HNRNPD-related disorder (25%, n = 3/12), and
poor gross motor coordination among probands with
HNRNPUL2-related disorder (33.3%, n = 2/6).
Physical abnormalities appear to be specific to certain
disorders. The exception to this are abnormalities of the
hands and feet (36.7%, n = 73/199, 9/12 disorders), in-
cluding small hands and feet, abnormalities of palmar
creases, clinodactyly and brachydactyly (the latter two
prevalent among probands with HNRNPR-related syn-
drome, 77.8%, n = 7/9 and 44.4%, n = 4/9, respectively,
clinodactyly significantly more prevalent among HNRN
PR probands compared to SYNCRIP [p = 0.02] and
HNRNPU probands [p = 0.0004]), among others with
less consistency. A subset of probands have growth delay
(30.5%, n = 61/200), particularly probands with variation
in HNRNPH1 (62.5%, n = 5/8), HNRNPH2 (47.8%, n =
11/23), HNRNPR (90%, n = 9/10, significantly more so
than HNRNPK probands [p = 0.03]), and HNRNPUL2
(50%, n = 3/6). Muscular abnormalities are common
(46.1%, n = 89/193), with hypotonia (44%) occurring
more often than hypertonia (6.2%). Hypertonia is rela-
tively specific to HNRNPUL1 variation (22.2%, n = 2/9).
Of eye abnormalities (41.2%, n = 82/199), strabismus is
the most common, observed frequently in HNRNPAB-
related disorder (66.7%, n = 2/3), HNRNPH1-related syn-
dromic ID (62.5%, n = 5/8), and HNRNPR-related syn-
drome (55.6%, n = 5/9). Hearing impairment is observed
primarily among probands with HNRNPH3 variation
(66.7%, n = 2/3), although with only three probands its’
unclear if this is characteristic of a majority of HNRN
PH3 variants. Skeletal morphological abnormalities (29.9%,
n = 59/197) are primarily observed among probands with
AKS (HNRNPK, 63%, n = 17/27 and HNRNPR-related syn-
drome (70%, n = 7/10). The most common among these
probands are abnormalities of curvature of the vertebral
column, including scoliosis and kyphosis (HNRNPK: 39.1%,
n = 9/23; HNRNPR: 33.3%, n = 3/9). Skeletal physiological
abnormalities, including joint hyper-extensibility or laxity,
only occur in 27.6% (n = 43/190) of probands over all, but
are particularly common among probands with HNRNPD-
related disorder (20%, n = 2/10), HNRNPH1-related syn-
dromic ID (50%, n = 4/8), Bain-type ID (39.1%, n = 9/23),
AKS (27.6%, n = 8/29), and SYNCRIP-related disorder
(26.1%, n = 6/23). Cardiac abnormalities are another known
AKS phenotype, occurring in half (50%, n = 15/30) of pro-
bands with AKS, but only 19.4% (n = 38/196) of all HNRNP
genetic disorder probands [13]. Genitourinary abnormal-
ities (21.5%, n = 43/200) are a known AKS phenotype
(63.3%, n = 19/30) and occur significantly more often
among probands with AKS (p = 0.02 compared to Bain-
type ID, p = 0.0001 compared to HNRNPU-related
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disorder). The most common genitourinary phenotypes ob-
served in AKS are vesicoureteral reflux (26.7%, n = 8/30)
and hydronephrosis (16.7%, n = 5/30). Enuresis is specific to
HNRNPD-related disorder (23.1%, n = 3/13), while hypo-
spadias is mostly specific to HNRNPH1-related syndromic
ID (40% of missense variants, n = 2/5).
Dysmorphic facies (56.8%, n = 113/199) tend to not be
consistent, although a few are seen among multiple dis-
orders, including ear abnormalities (AKS, HNRNPR-re-
lated syndrome, HNRNPD-related disorder, and HNRN
PU-related disorders), small nasal alae (HNRNPH1-re-
lated syndromic ID and AKS), microcephaly (AKS,
HNRNPH1-related disorder, HNRNPR-related syndrome,
and HNRNPU-related disorder), and round faces (HNRN
PD-related disorder, Bain-type ID, and HNRNPR-related
syndrome) (Additional File 1: Table S7). HNRNPD-re-
lated disorder most consistently results in a round face
(23.1%, n = 3/13) and large ears (25%, n = 3/12). HNRN
PH1-related syndromic ID probands tend of have hypo-
plastic alae (25%, n = 2/8). Bain-type ID probands tend to
have abnormal palpebral fissures (22.7%, n = 5/22), con-
sistent with the almond-shaped eyes previously reported
for this syndrome. AKS dysmorphic features have been
previously described and also consist of cleft palate (31%,
n = 9/29), downturned corners of the mouth (20.7%, n = 6/
29), an open bite (20.7%, n = 6/29), teeth abnormalities
(17.2%, n = 5/29), a wide nasal bridge (31%, n = 9/29), shal-
low orbits/prominent eyes (20%, n = 6/30 each), long pal-
pebral fissures (41.4%, n = 11/26), ptosis (30%, n = 9/30),
abnormal eyebrows (20.7%, n = 6/29), metopic ridging
(24.1%, n = 7/29), and abnormal nipples (20%, n = 6/30),
all of which are more prevalent among probands with
LGD variants [13]. HNRNPR probands have a large range
of facies as well, including micro/retrognathia (50%, n = 4/
8), teeth abnormalities (50%, n = 4/8), anteverted nares
(37.5%, n = 3/8), a low hanging columella (25%, n = 2/8), a
narrow forehead (37.5%, n = 3/8), up-slanted palpebral fis-
sures (37.5%, n = 3/8), unusual hair (37.5%, n = 3/8), a
broad and short neck (22.2%, n = 2/9), and brachycephaly
(22.2%, n = 2/9).
Other HNRNP genes
In addition to HNRNPs with multiple cases of disruptive
DNVs, we identified seven with less than three cases:
HNRNPA0 (n = 2, missense), HNRNPA1 (n = 1, mis-
sense), HNRNPA3 (n = 1, missense), HNRNPA2B1 (n = 2,
LGD), HNRNPC (n = 2, 1 LGD and 1 missense), HNRN
PLL (n = 1, missense), and PTBP2 (n = 1, missense)
(Additional File 1: Table S10). Four of these seven
(HNRNPA0, HNRNPA3, HNRNPA1, and HNRNPA2B1)
are in a group closely related to an NDD hnRNP group
(group 2; Fig. 1), suggesting that they may be implicated
in NDDs, but mutations occur much less frequently.
These were not included in the de novo or phenotypic
statistical analyses but may be of importance for future
screening of patients for candidate NDD-related genes.
Comparison to similar disorders
It is plausible that similarities observed between
HNRNP-related disorders may be due to ascertainment
and that our HNRNP-related disorders may actually have
more similarities to other known genetic disorders. To
address this, we compared each disorder’s characteristic
features to those of known NDDs (Fig. 7). HPO terms
that occur in 20% or more probands were entered into
the PhenPathTOOL and genes sharing the most HPO
terms were compared to the expression of the HNRNP
(Additional File 1: Table S12) [86]. HPO terms are
shared with SLC6A8 (cerebral creatine deficiency syn-
drome 1), CREBBP (Rubenstein-Taybi syndrome),
MECP2 (Rett syndrome, mental retardation, X-linked
syndromic, Lubs type), KANSL1 (Koolen-de Vries syn-
drome), RAI1 (Smith-Magenis syndrome), PTEN, SNRP
N, MAP 2K2, FGFR3, KMT2A, MED12, NDN, and
NAA10. Notably, AKS has been suggested to be similar
to Kabuki syndrome, although they do not share the
most HPO terms. Additionally, methylation analyses
have shown that these disorders have distinct profiles,
suggesting that their shared clinical features are likely
not simply due to shared genetic causes (Au et al.,
ASHG poster 3117). The number of genes with similar
phenotypes that overlap between the HNRNPs highlights
their shared phenotypic spectra. While there are similar-
ities with other NDDs, correlation of HPO terms present
for each disorder is higher among the HNRNP-related
disorders, suggesting they may have shared molecular
pathogenesis (p = 0.0013, paired t-test, Fig. 8a).
We assessed if shared gene expression is seen among
similarly presenting disorders in developing cortical tis-
sues (Fig. 8b, Additional File 2: Fig. S6). While there is a
positive correlation (Pearson’s R > 0.5) among almost all
genes in our analyses, correlations between genes with
shared HPO terms are lower than those among the
HNRNPs (Fig. 7c). This suggests that, while there are
some shared expression patterns that are likely involved
in neurodevelopment broadly, the HNRNP-related gen-
etic disorders are indeed a unique family based on gene
expression.
Discussion
The goal of this study was to investigate genotype–
phenotype correlations in the context of a molecularly
related gene family. We selected the HNRNPs because
they have been implicated in NDDs due to rare missense
and LGD variation, as well as neurodegenerative disease
and cancers primarily through changes in function, ex-
pression, and/or localization (Table 1) [8, 9, 12–14, 18,
20–23, 25, 27, 28, 89–103]. In addition, HNRNPs are
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candidates for haploinsufficiency for multiple contiguous
gene deletion syndromes resulting in NDDs (HNRNPK,
SYNCRIP, and HNRNPU, and likely HNRNPD and
HNRNPR). More recently, SNVs and indels in HNRNPU,
HNRNPK, HNRNPH1/2, and HNRNPR have been re-
ported in probands with NDDs, and HNRNPU and
SYNCRIP show an excess of DNVs in individuals with
NDDs from recent large-scale sequencing studies [11–
18, 20–23, 25–27, 35–39, 41, 58, 60, 104–106]. Thus, we
hypothesized that there are (1) similar phenotypic (clin-
ical and molecular) spectra across these disorders due to
shared structure and function and (2) additional
HNRNP-related disorders yet to be observed.
From our analyses, we identified 12 HNRNPs as par-
ticularly relevant to NDDs, which we term NDD
HNRNPs: HNRNPAB, HNRNPD, HNRNPF, HNRNPH1,
HNRNPH2, HNRNPH3, HNRNPK, HNRNPR, SYNCRIP,
HNRNPU, HNRNPUL1, and HNRNPUL2. Multiple lines
of evidence, including protein homology, expression ana-
lysis, and mutation intolerance, indicate that genes/pro-
teins within this group are more molecularly related and
more sensitive to variation than the other HNRNP family





































































































































































































































































































































Fig. 8 Relationship of HNRNP-related disorders to each other and to similarly presenting disorders. a Comparison of average number of HPO
terms shared within HNRNPs versus with other similarly presenting disorders, as determined by PhenPath. The HNRNP-related disorders present
more similarly to each other than other NDDs. HPO terms are in Table S12. b Heatmap showing fold change of expression of each NDD HNRNP
and similarly presenting NDD based on HPO terms among 48 different cell types. Blue indicates increase in fold change of expression and red
indicates decreased expression, as determined by Z-scores. c Correlation plot of developing fetal cortex gene expression for HNRNPs and genes
implicated in similarly presenting disorders. Pearson correlation R values shown visually, with darker and larger circles indicating higher Pearson R
values. HNRNPs are noted with a red line. P values were corrected by number of genes [28] and number of cell types [48]. *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001. d Comparison of expression Pearson’s R values within HNRNPs and compared to similarly presenting disorders. The
expression of the HNRNPs is more similar to each other than to other NDDs
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members. In addition to the five HNRNPs previously im-
plicated in NDDs, we report seven new HNRNPs as can-
didates for emerging disorders and have integrated and
compared their phenotypic features (Fig. 7, Additional
File 1: Tables S7) [19, 38, 66, 104].
From over 80,000 individuals, we identify 225 pro-
bands (115 novel) with likely pathogenic SNVs and
indels among the NDD HNRNPs—almost all of which
with known inheritance are de novo (Table 2, Fig. 5).
This study, thus, increases the sample size for de novo
analyses by almost eightfold when compared to previous
surveys, identifying a third gene family member, HNRN
PD, that achieves nominal significance for an excess of
de novo LGD or missense mutations in comparison to
chimpanzee– and macaque–human mutation models
(Fig. 4a). With a larger sample size, we predict that most
of these NDD HNRNPs will ultimately become signifi-
cantly associated with an excess of DNVs. Due to the
limitations of these models and modes of ascertainment,
many variants were not considered in de novo analyses
(n = 147/225 not in analyses); therefore, we are under-
estimating the significance of variation in these genes.
Overall, in large cohorts evolutionary mutational model-
ing provides a valuable resource for gene discovery and
statistical support for NDD genes but still may miss rare
disorders that are observed in the clinic. Additionally,
we identified multiple disorders (HNRNPF-, HNRNPH3-,
HNRNPUL1-, and HNRNPUL2-related disorders) that
were not identified in the clinic or by previous statistical
analyses, but by comparison to known NDDs. This high-
lights the need for intersection between statistical mod-
eling, clinical identification, and novel approaches to
identifying NDD candidate genes to uncover the rarest
of disorders.
Our results support emerging syndromes associated
with seven genes and expand upon known HNRNP-re-
lated disorders [10, 19, 38, 66, 104]. We are able to ex-
plain some of the phenotypic similarities and differences
based on protein homology, gene expression—which is
highly correlated among almost all HNRNPs—and
known shared function. At cell type resolution, NDD
HNRNP expression is most strongly enriched among
progenitor populations of the human cerebral cortex
and MGE, including mitotic radial glia, and their expres-
sion is depleted in both early-born excitatory neurons
and newborn MGE neurons (Fig. 6b, Additional File 2:
S3A,B). Radial glia, one of the earliest cells found in
brain development, act as neural stem cells of the cere-
bral cortex and are important in the differentiation and
migration of many neuronal cell types. Enriched expres-
sion of NDD HNRNPs in actively dividing radial glia
suggests a possibility that disruption of hnRNPs may
lead to aberrant neuronal development. Disruption of ra-
dial glia can happen at many steps in early development,
including changes in proliferation leading to differing
number of neurons, changes in scaffolding leading to
impaired neuronal migration, and subtler defects in
neurite extension, synaptogenesis, and neuronal con-
nectivity [107–109]. These types of changes have been
detected in ASD, DD/ID, epilepsy, and schizophrenia.
Interestingly, some NDD hnRNPs have already been im-
plicated in cell division through cancer studies, including
hnRNPD, hnRNPK, SYNCRIP, and hnRNPU [110–114].
Thus, it is plausible that altered cell division, differenti-
ation, and neuronal migration may be playing a role in
the pathogenesis of HNRNP variation. At a brain region
level, we see enrichment in the early fetal striatum and
the early-mid fetal amygdala, both of which have been
implicated in NDDs [1, 115–117]. At the adult tissue
level, it is clear that HNRNPK has the highest and most
ubiquitous expression, which may account for some of
the more physical phenotypes observed in probands with
AKS. hnRNPR is also known to regulate HOX genes,
which likely plays a role in the physical manifestations
seen in HNRNPR-related disorder, and dysregulation of
HOX genes may be important to other HNRNP-related
disorders as well [18]. Overall, we observe that missense
variants cluster for all hnRNPs more so among probands
than controls, and especially for hnRNPH2, hnRNPK,
hnRNPR, and hnRNPUL1, and that particular protein
domains appear to be impacted, including RNA- and
DNA-binding domains.
Consistent with our ascertainment, DD/ID are the
most prevalently shared features among all probands
with HNRNP-related disorders, which may be due to as-
certainment bias (Fig. 7). Over half have speech delay
and over 40% have seizures and/or hypotonia, while over
one third each have structural brain abnormalities or
ASD. Structural brain abnormalities include abnormal-
ities of the corpus callosum, cerebellar vermis hypopla-
sia, and dysmorphic ventricles, which may be explained
by the high radial glia expression of HNRNPs. Most have
some dysmorphic features, and several have a range of
physical abnormalities impacting the cardiac, skeletal,
and genitourinary systems, although generally these are
inconsistent, except for AKS and HNRNPR-related syn-
drome, which have been previously described (Add-
itional File 1: Table S7) [13, 18].
While there is subjectively a pattern of phenotypes, we
also observe a strong correlation between almost all of
the HNRNP-related disorders, as hypothesized given
they have similar molecular structure and function and
shared gene expression (Fig. 7a). Notably, we observe
that phenotypic correlations follow a similar pattern to
those of protein homology, suggesting that more similar
proteins molecularly do have more similar consequences
when disrupted (Fig. 7b). HNRNPF-related disorder has
the weakest correlations, although this is likely due to
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(1) lower sample size (n = 3) with limited phenotypic in-
formation and (2) a potential association with autism
without intellectual disability (n = 1/2 with ASD and no
DD/ID) [34]. There are similar patterns in correlations
based on LGD and severe missense variation, highlight-
ing the shared impacts of the two types of variants on
each gene (Additional File 2: Fig. S4). While we have far
fewer probands with missense variation, they typically
have a less severe phenotype, and their pathogenic sig-
nificance remains to be determined given the small sam-
ple size.
Overall, our phenotypic analyses of the previously re-
ported HNRNPU-related disorder, AKS, Bain-type ID,
HNRNPH1-related syndromic ID, and HNRNPR-related
syndrome are consistent with what has been published
[12, 13, 18, 20–23, 25–27, 60]. We generally find that
the phenotypic spectrum of newly recruited patients
matches what has previously been reported for LGD
mutations, although the phenotypic consequences of
missense variation are less well established. Only a few
differences were observed. One is that our data do not
support the previous suggestion that probands with
HNRNPU-related disorder have renal and cardiac abnor-
malities, or these phenotypes have much lower pene-
trance. Another is that ASD has a higher prevalence
than previously reported for AKS, particularly for mis-
sense variants. We also provide evidence phenotypically
and based on gene expression that HNRNPH1-related
syndromic ID and Bain-type ID (HNRNPH2) are indeed
independent disorders, which has been under debate.
Also supporting this are the variant types, which cluster
in the M9 nuclear targeting region of hnRNPH2, likely
impacting its localization and global translation based on
in vitro work, but are seen across the entirety of
hnRNPH1 [118, 119].
We report seven novel disorders: SYNCRIP-, HNRN
PD-, HNRNPUL1-, HNRNPUL2-, HNRNPAB-, HNRN
PF-, and HNRNPAB-related disorders. Both SYNCRIP
and HNRNPD have been NDD candidates due to being
in the critical region of genomic disorders (Table 3).
SYNCRIP, having high protein homology to hnRNPR,
has also been observed to have recurrent de novo LGD
variants in large NDD sequencing studies [39, 69, 74].
Indeed, we see support of this both phenotypically and
statistically, with SYNCRIP LGD variants reaching
exome-wide significance by the CH model (Fig. 5). We
propose that SYNCRIP-related disorder primarily mani-
fests as DD/ID, ASD, ADHD, hypotonia, speech delay,
and structural brain abnormalities (including abnormal/
dysmorphic ventricles, abnormalities of the corpus callo-
sum, and Chiari malformations), with some probands
having abnormal gait or ataxia, hyper-extensible joints,
and hand and feet abnormalities (Additional File 1:
Table S7). Many SYNCRIP RNA and protein interactors
are critical in neuronal RNA and membrane trafficking,
synaptic plasticity, axonogenesis, neuronal morphology,
and dendritic translation [120–125].
Probands with HNRNPD-related syndrome show a
high prevalence of DD/ID, speech delay, and ASD and/
or other behavioral phenotypes (Additional File 1: Table
S7) [55]. These probands also have consistent facial fea-
tures of a round face, epicanthus, and large ears. Other
emotional disturbances are also noted, including aggres-
sion, intermittent explosive disorder, and depression. It
has been suggested that the gene may play a role in the
development of enkephalinergic neurons, known to be
important in neurodevelopment, particularly for emo-
tional responses and ASD, which aligns with more emo-
tional disturbances in HNRND probands [126, 127].
HNRNPD expression is also altered following NMDA re-
ceptor stimulation, which may impact the wide range of
intracellular cascades, including those involved in cell
survival, differentiation, and neuroplasticity.
hnRNPUL1 and hnRNPUL2 have high protein hom-
ology to hnRNPU, although they appear to have milder
phenotypes when disrupted. HNRNPUL1-related dis-
order consists of DD/ID, although about half as often as
with HNRNPU variation, short stature, motor and
speech delay, structural brain, skeletal, and cardiac ab-
normalities, abnormal gait, ASD, failure to thrive, and
hypertonia (Additional File 1: Table S7). Previously, it
was suggested that missense variation in HNRNPUL1
contributes to “high-functioning” autism, meaning an
autism diagnosis and IQ in the normal range, which our
data support [34]. Missense variants cluster significantly
among probands compared to controls, although not in
a clear protein domain, suggesting that disruption within
that part of the protein may be responsible for some
phenotypes (Fig. 4). Probands with HNRNPUL2-related
disorder exhibit DD/ID, ASD, and motor and speech
delay. HNRNPUL2 gene expression has also been shown
to be significantly decreased in the blood of first episode
psychosis patients, suggesting a neuronal functional role
and that we may have under-ascertained individuals with
neuropsychiatric phenotypes [128]. Although understud-
ied, both HNRNPUL1 and HNRNPUL2 are known to be
critical in the DNA damage response, which has been
associated with neurodevelopment [129–132].
Three of our novel disorders only have three probands
each: HNRNPAB-, HNRNPF-, and HNRNPH3-related
disorders, making it difficult to draw conclusions. For
probands with HNRNPAB variants, DD/ID is common,
as are delayed speech and language, ASD, hypotonia,
and strabismus. Little is known about hnRNPAB outside
of cancer, but it has been shown to regulate expression
of neurodevelopmental genes and those involved in glu-
tamate signaling, as well as neural cell motility [133,
134]. Probands with HNRNPH3-related disorder have a
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high prevalence of DD/ID, like the other HNRNPH dis-
orders, although they manifest characteristic hearing loss
as well. However, the gene expression is shared with
both other HNRNPH genes, suggesting that their shared
phenotypes may have similar molecular causes and that
additional probands may reveal a stronger phenotypic
relationship. hnRNPF is highly homologous to
hnRNPH1/2/3 (Fig. 2, group 7), and like those genes, we
identified only reports of severe missense variation. Thus,
HNRNPF-related disorder may have more molecular simi-
larities to HNRNPH-related disorders, although with only
three probands this is difficult to conclude. All probands
have ASD, and half have DD/ID, suggesting that autism
with a normal IQ may be an associated phenotype as pre-
viously suggested (Table S7) [34]. While little is known
about the specific function of hnRNPF, it is has been
shown to interact with other hnRNPH proteins and regu-
late neuronal-specific splicing, as well as myelin basic pro-
tein synthesis in oligodendrocytes [135, 136]. The lack of
LGD variants in our cohort as well as gnomAD for HNRN
PH2, HNRNPH3, and HNRNPF may suggest that loss-of-
function mutations are embryonic lethal.
As there are some shared features among NDDs over-
all, we wanted to ensure that the common phenotypes
and expression were specific among our HNRNP-related
disorders compared to similarly presenting disorders.
While several disorders share multiple HPO terms with
our HNRNP-related disorders, the HNRNP-related disor-
ders are more similar to each other than to other NDDs.
It is plausible that similarly presenting disorders share
disrupted gene regulation with the HNRNP-related dis-
orders, explaining some shared phenotypes. Based on
gene expression in the developing fetal cortex, the ex-
pression of the HNRNPs are more similar to each other
than similarly presenting disorders (Fig. 8c,d). Thus, we
conclude that, while of course there are many disorders
that may share phenotypes, the HNRNP-related disor-
ders are unique in their presentation and gene expres-
sion, as well as protein function, supporting a gene
family approach.
Our study highlights the value and challenge of inte-
grating data across multiple centers and the published
literature for a group of highly heterogeneous NDDs. A
strength is our large sample size of > 80,000 individuals,
pulling from published work, our own unpublished re-
sources, and international collaborations, but for rare
disorders this is still insufficient. As shown by our de
novo mutation analyses, the sample sizes used are not
high enough to detect evolutionary evidence that vari-
ation in many of these genes is pathogenic, but based on
clinical patterns, protein homology, and gene expression,
there is reason to conclude pathogenicity. Multiple
HNRNPs have been implicated in autism with normal
IQ and/or neuropsychiatric disorders that have little
effect on IQ, which are severely under-ascertained not
only in this study but across the board in NDD research.
Additionally, the average age of patients in our study is
10.5 years, suggesting that any phenotypes associated
with adults are likely missed. Thus, while much of our
data shows that there are not many significant differ-
ences among HNRNP-related disorders, this is likely not
the full story of these disorders. Much work is needed to
establish the molecular phenotypes to fully understand
the pathophysiology of these disorders, which will deter-
mine if there are shared pathways affected by these dis-
orders and inform potential treatment strategies.
Conclusions
In summary, the hnRNPs are a family of proteins that
have been shown repeatedly to impact neurological dis-
ease. Here, we establish both a statistical enrichment of
DNVs and phenotypic evidence that many of the
HNRNPs are involved in NDDs. The conservation,
shared expression, and phenotypic consequences clearly
support a subset of these as high likelihood candidates
of NDD when mutated. More work is necessary to
understand the molecular underpinnings of NDD-
related HNRNP variation, especially since compounds
utilized in diseases such as addiction and cancer are
available to target, both up- and downregulating, a sub-
set of hnRNPs [83, 137]. Future work may identify
hnRNP-targeting compounds and/or downstream-
targeting compounds that could prove to be efficacious
in modifying patient outcomes. With the shared func-
tion, localization, and binding targets of many of the
NDD hnRNPs, it is likely that one compound may bene-
fit probands with changes in related genes. Using the
hnRNPs as an example, we have provided an evidence-
based foundation supporting that, by identifying relevant
NDD gene families and distinguishing molecularly re-
lated subgroups, characterization of de novo mutated
genes among NDDs can be performed more effectively.
This facilitates improved diagnosis and prospective as-
sessment of NDDs as well as potential future develop-
ment of more impactful therapeutics, while also
providing information on neurodevelopment as a whole.
Abbreviations
ADHD: Attention deficit hyperactivity disorder; AKS: Au-Kline syndrome;
ALS: Amyotrophic lateral sclerosis; ANOVA: Analysis of variance; ASD: Autism
spectrum disorder; BGL: Baylor Genetics Laboratory; CH model: Chimpanzee–
human divergence model; CLUMP: CLUstering by Mutation Position;
CNV: Copy number variant; DD: Developmental delay; DDD: Deciphering
Developmental Disorders; DNA: Deoxyribonucleic acid; DNV: De novo variant;
FTLD: Frontotemporal lobar degeneration; GERD: Gastroesophageal reflux
disease; GeVIR: Gene Variation Intolerance Rank; hnRNP/
HNRNP: Heterogeneous nuclear ribonucleoprotein (hnRNP for protein, HNRNP
for gene); HPO: Human Phenotype Ontology; ID: Intellectual disability;
LGD: Likely gene disrupting; MIS: Missense; MIS20: Missense variant with
CADD score ≥ 20; MIS30: Missense variant with CADD score ≥ 30;
NDD: Neurodevelopmental disorder; NMDA: N-methyl-D-aspartate receptor;
Gillentine et al. Genome Medicine           (2021) 13:63 Page 20 of 26
Content courtesy of Springer Nature, terms of use apply. Rights reserved.
pLI: Probability of loss of function; RNA: Ribonucleic acid; SEA: Specific
Expression Analyses; SNV: Single-nucleotide variant
Supplementary Information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13073-021-00870-6.
Additional file 1: Supplementary Tables S1-S12. Table S1. Cohorts
utilized in current study. Table S2. Pathogenicity predictions by gnomAD
and GeVIR for each hnRNP. Table S3. Significant p values of two-way
ANOVA between cell type and transcripts per million (TPM) for each NDD
HNRNP’s GTEx data. Table S4. P values and fold change for scRNA data
from developing human cortex. Table S5. Significant p values of two-way
ANOVA between cell type and fold expression for each HNRNP. Table S6.
De novo enrichment and CLUMP analyses of current cohort. Table S7.
Phenotypes among HNRNP-related disorders. Table S8. Uncorrected p
values for pairwise Fisher’s exact tests for each phenotype occurring in
20% of an HNRNP group. Table S9. Uncorrected p values for phenotype
correlations between each HNRNP-related disorder. Table S10. Variants
and phenotypes for HNRNPs with < 3 probands. Table S11. Probands with
copy number variants. Table S12. Shared HPO terms with similarly pre-
senting genetic disorders.
Additional file 2: Supplementary Figures S1-S5. Fig. S1. Dendrogram
of hnRNPs based on multiple sequence alignment of canonical amino
acid sequences. Colors match those seen in Fig. 2. NDD hnRNPs are
shown in black boxes. Fig. S2. Pathogenicity assessment of variation in
hnRNPs. A) Gene Variation Intolerance Ranking (GeVIR), loss-of-function
observed/expected upper bound fraction (LOEUF), and Variation Intoler-
ant Region Loss-of-Function (VIRLoF) percentiles. Average LOEUF percent-
ile is significantly higher for NDD HNRNPs (n = 13) compared to other
HNRNPs (n = 15). B) Average fold change for GeVIR, LEOUF, and VIRLoF for
autosomal dominant (AD) and autosomal recessive (AR) variants. Average
LEOUF fold change for AD mutations is significantly higher for NDD
HNRNPs compared to other HNRNPs, with the AD VIRLoF fold change
trending in the same direction. The AR LEOUF fold change is trending to-
wards being significantly higher among other HNRNPs compared to NDD
HNRNPs. One-way t-test. * p < 0.05. Fig. S3. Expression of HNRNPs among
adult tissues and the developing human cortex. A) Heatmap of all HNRNP
expression in developing cortex tissues. B) Comparison of fold expression
of NDD HNRNPs to non-NDD HNRNPs. C) Heatmap of all HNRNP expres-
sion (transcript level expression) in adult brain tissues from GTEx. D) Heat-
map of NDD HNRNP expression (transcript level expression) in all tissues
from GTEx. Fig. S4. Phenotypic correlations for LGD and missense variant
probands. A) Correlation matrix of phenotypes across HNRNP probands
with LGD variation (genes with only missense variation excluded) and B)
severe missense variation (genes with only LGD variation excluded. * p <
0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. Fig. S5. Phenotypic compar-
isons between LGD and missense variants by HNRNP. Fig. S6. GTEx ex-
pression of NDD HNRNPs and genes associated with similarly presenting
disorders.
Additional file 3: Table S13. GenBank accession numbers.
Acknowledgements
We thank all of the families participating in this study. We are grateful to all
of the families at the participating SSC sites, as well as the principal
investigators (A. Beaudet, R. Bernier, J. Constantino, E. Cook, E. Fombonne, D.
Geschwind, R. Goin-Kochel, E. Hanson, D. Grice, A. Klin, D. Ledbetter, C. Lord,
C. Martin, D. Martin, R. Maxim, J. Miles, O. Ousley, K. Pelphrey, B. Peterson, J.
Piggot, C. Saulnier, M. State, W. Stone, J. Sutcliffe, C. Walsh, Z. Warren, E. Wijs-
man). We appreciate obtaining access to phenotypic data on SFARI Base for
both SSC and SPARK samples, as well as SPARK exome data from the SPARK
Consortium. Approved researchers can obtain the SSC population dataset
described in this study (https://www.sfari.org/resource/resources/simons-
simplex-collection/) by applying at https://base.sfari.org. We thank the DDD
study, which presents independent research commissioned by the Health
Innovation Challenge Fund (grant number HICF-1009-003), a parallel funding
partnership between the Wellcome Trust and the Department of Health, and
the Wellcome Trust Sanger Institute (grant number WT098051). The views
expressed in this publication are those of the authors and not necessarily
those of the Wellcome Trust or the Department of Health. The study has UK
Research Ethics Committee approval (10/H0305/83, granted by the Cam-
bridge South REC, and GEN/284/12 granted by the Republic of Ireland REC).
The research team acknowledges the support of the National Institute for
Health Research, through the Comprehensive Clinical Research Network. The
authors would like to thank the University of Washington Center for Mendel-
ian Genomics and all contributors to MyGene2 for use of data included in
MyGene2. The Genotype-Tissue Expression (GTEx) Project was supported by
the Common Fund of the Office of the Director of the National Institutes of
Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The content is
solely the responsibility of the authors and does not necessarily represent
the official views of the NIH. We thank Emily Guilbert for aid in recontacting
a family included in this study. We thank Tonia Brown for assistance in edit-
ing this manuscript and Amy Wilfert for advice on statistics.
Consortia
SPARK Consortium: John Acampado 1, Andrea J. Ace 1, Alpha Amatya 1, Irina
Astrovskaya 1, Asif Bashar 1, Elizabeth Brooks 1, Martin E. Butler 1, Lindsey A.
Cartner 1, Wubin Chin 1, Wendy K. Chung 1,2, Amy M. Daniels 1, Pamela
Feliciano 1, Chris Fleisch 1, Swami Ganesan 1, William Jensen 1, Alex E. Lash1,
Richard Marini 1, Vincent J. Myers 1, Eirene O’Connor 1, Chris Rigby 1, Beverly
E. Robertson1, Neelay Shah 1, Swapnil Shah 1, Emily Singer 1, LeeAnne G.
Snyder 1, Alexandra N. Stephens 1, Jennifer Tjernagel 1, Brianna M. Vernoia 1,
Natalia Volfovsky 1, Loran Casey White1, Alexander Hsieh 2, Yufeng Shen 2,
Xueya Zhou 2, Tychele N. Turner 3, Ethan Bahl 4, Taylor R. Thomas 4, Leo
Brueggeman 4, Tanner Koomar 4, Jacob J. Michaelson 4, Brian J. O’Roak 5,
Rebecca A. Barnard 5, Richard A. Gibbs 6, Donna Muzny 6, Aniko Sabo 6, Kelli
L. Baalman Ahmed 6, Evan E. Eichler 7, Matthew Siegel 8, Leonard Abbeduto
9, David G. Amaral 9, Brittani A. Hilscher 9, Deana Li 9, Kaitlin Smith 9,
Samantha Thompson 9, Charles Albright 10, Eric M. Butter 10, Sara Eldred 10,
Nathan Hanna 10, Mark Jones 10, Daniel Lee Coury 10, Jessica Scherr 10, Taylor
Pifher 10, Erin Roby 10, Brandy Dennis 10, Lorrin Higgins 10, Melissa Brown 10,
Michael Alessandri 11, Anibal Gutierrez 11, Melissa N. Hale 11, Lynette M.
Herbert 11, Hoa Lam Schneider 11, Giancarla David 11, Robert D. Annett 12,
Dustin E. Sarver 12, Ivette Arriaga 13, Alexies Camba 13, Amanda C. Gulsrud 13,
Monica Haley 13, James T. McCracken 13, Sophia Sandhu 13, Maira Tafolla 13,
Wha S. Yang 13, Laura A. Carpenter 14, Catherine C. Bradley 14, Frampton
Gwynette 14, Patricia Manning 15, Rebecca Shaffer 15, Carrie Thomas 15,
Raphael A. Bernier 16, Emily A. Fox 16, Jennifer A. Gerdts 16, Micah Pepper 16,
Theodore Ho 16, Daniel Cho 16, Joseph Piven 17, Holly Lechniak 18, Latha V.
Soorya 18, Rachel Gordon 18, Allison Wainer 18, Lisa Yeh 18, Cesar Ochoa-
Lubinoff 19, Nicole Russo 19, Elizabeth Berry-Kravis 20, Stephanie Booker 21,
Craig A. Erickson 21, Lisa M. Prock 22, Katherine G. Pawlowski 22, Emily T. Mat-
thews 22, Stephanie J. Brewster 22, Margaret A. Hojlo 22, Evi Abada 22, Elena
Lamarche 23, Tianyun Wang 24, Shwetha C. Murali 24, William T. Harvey 24,
Hannah E. Kaplan 25, Karen L. Pierce 25, Lindsey DeMarco 26, Susannah Horner
26, Juhi Pandey 26, Samantha Plate 26, Mustafa Sahin 27, Katherine D. Riley 27,
Erin Carmody 27, Julia Constantini 7, Amy Esler 28, Ali Fatemi 29, Hanna Hutter
29, Rebecca J. Landa 29, Alexander P. McKenzie 29, Jason Neely 29, Vini Singh
29, Bonnie Van Metre 29, Ericka L. Wodka 29, Eric J. Fombonne 30, Lark Y.
Huang-Storms 30, Lillian D. Pacheco 30, Sarah A. Mastel 30, Leigh A. Coppola
30, Sunday Francis 31, Andrea Jarrett 31, Suma Jacob 31, Natasha Lillie 31, Jaclyn
Gunderson 31, Dalia Istephanous 31, Laura Simon 31, Ori Wasserberg 31, An-
gela L. Rachubinski 32, Cordelia R. Rosenberg 32, Stephen M. Kanne 33,34,
Amanda D. Shocklee 34, Nicole Takahashi 34, Shelby L. Bridwell 34, Rebecca L.
Klimczac 34, Melissa A. Mahurin 34, Hannah E. Cotrell 34, Cortaiga A. Grant 34,
Samantha G. Hunter 34, Christa Lese Martin 35, Cora M. Taylor 35, Lauren K.
Walsh 35, Katherine A. Dent 35, Andrew Mason 36, Anthony Sziklay 36, Christo-
pher J. Smith 36.
1 Simons Foundation, New York, USA
2 Columbia University, New York, USA
3 Washington University School of Medicine, St. Louis, USA
4 University of Iowa Carver College of Medicine, Iowa City, USA
5 Oregon Health & Science University, Portland, USA
6 Baylor College of Medicine, Houston, USA
7 University of Washington School of Medicine, Howard Hughes Medical
Institute, Seattle, USA
8 Maine Medical Center Research Institute, Portland, USA
9 University of California, Davis, Sacramento, USA
10 Nationwide Children’s Hospital, Columbus, USA
11 University of Miami, Coral Gables, USA
12 University of Mississippi Medical Center, Jackson, USA
Gillentine et al. Genome Medicine           (2021) 13:63 Page 21 of 26
Content courtesy of Springer Nature, terms of use apply. Rights reserved.
13 University of California, Los Angeles, Los Angeles, USA
14 Medical University of Southern Carolina (MUSC), Portland, USA
15 Cincinnati Children’s Hospital Medical Center – Research Foundation,
Cincinnati, USA
16 Seattle Children’s Autism Center/UW, Seattle, USA
17 University of North Carolina at Chapel Hill, Chapel Hill, USA
18 Department of Child & Adolescent Psychiatry, Rush University Medical
Center, Chicago, USA
19 Department of Developmental & Behavioral Pediatrics, Rush University
Medical Center, Chicago, USA
20 Department of Neurological Sciences, Department of Pediatrics,
Department of Biochemistry, Rush University Medical Center, Chicago, USA
21 Cincinnati Children’s Hospital Medical Center – Research Foundation,
Cincinnati, USA
22 Boston Children’s Hospital (BCH), Boston, USA
23 University of North Carolina at Chapel Hill, Chapel Hill, USA
24 University of Washington School of Medicine, Seattle, USA
25 University of California, San Diego, School of Medicine, La Jolla, USA
26 Children’s Hospital of Philadelphia, Philadelphia, USA
27 Boston Children’s Hospital (BCH), Boston, USA
28 University of Minnesota, Minneapolis, USA
29 Kennedy Krieger Institute, Baltimore, USA
30 Oregon Health & Science University, Portland, USA
31 University of Minnesota, Minneapolis, USA
32 University of Colorado School of Medicine, Aurora, USA
33 Department of Health Psychology, University of Missouri, Columbia, USA
34 Thompson Center for Autism and Neurodevelopmental Disorders,
University of Missouri, Columbia, USA
35 Geisinger Autism & Developmental Medicine Institute, Lewisburg, USA
36 Southwest Autism Research and Resource Center, Phoenix, USA
Authors’ contributions
M.A.G. and E.E.E. led the conception and design of the work and manuscript
drafting. T.W. and K.H. performed sequencing on ASID samples, and T.W.
participated in analysis of SPARK data. J.R. and P.L. analyzed and contributed BGL
data. R.A.B., R.K.E., M.P., and H.P. collected and provided data from probands at the
UW Autism Center, as well as information from probands in the SSC and other
cohorts. E.T. provided information on probands from GeneDx. C.N.K. and T.N.
analyzed and contributed the scRNA-seq data. B.B.A.d.V and L.E.L.M.V. provided gen-
omic and phenotypic data on RUMC probands. All other authors provided pheno-
typic information on probands. All authors read and approved the final manuscript.
Funding
This work was supported, in part, by the U.S. National Institutes of Health
(R01MH101221) to E.E.E. Research reported in this publication was supported, in part,
by the National Institute of Neurological Disorders and Stroke (NINDS) under award
number K08NS092898, Jordan’s Guardian Angels, and the Brotman Baty Institute (to
G.M.M.). M.I., A.C., and A.S. were supported by the G.E.N.E. (Genomic analysis Evaluation
Network) Research Project founded by Progetti di Innovazione in Ambito Sanitario e
Socio Sanitario (Bando EX decreto n.2713 28.02.2018) Regione Lombardia. D. L was
supported by the German Research Foundation (DFG; LE 4223/1). B.B.A.d.V. and
L.E.L.M.V. were supported by grants from the Dutch Organization for Health Research
and Development (ZON-MW grants 917–86–319 and 912–12–109). M.E., O.G., and C.R.
received funding from the Italian Ministry of Health (Project RC n. 2757328). I.T. is
supported by generous donors to the Children’s Mercy Research Institute and the
Genomic Answers for Kids program. K.X. is supported by the National Natural Science
Foundation of China (NSFC: 8173000779) and the Science and Technology Major
Project of Hunan Provincial Science and Technology Department (2018SK1030). M.A.G.
was supported by the U.S. National Institutes of Health (T32HG000035). E.E.E. is an
investigator of the Howard Hughes Medical Institute.
Availability of data and materials
All data from probands generated or analyzed during this study are included
in this published article and its supplementary information files. Accession
numbers can be found in Additional File 3: Table S13 [138]. All other data is


























UCSC Cell Browser: https://cells.ucsc.edu
Uniprot: http://uniprot.org
Declarations
Ethics approval and consent to participate
Probands or their families were contacted directly and consented by the
University of Washington Autism Center under the TIGER study (IRB#:
STUDY00000813) to participate in the study. Patient samples were obtained
from the ASID network with informed consent, and all clinical recontact
performed on the individuals in this study were approved by the University of
Washington Institutional Review Board (IRB), in accordance with the ethical
standards of the responsible local institutional and national committees.
Consent for publication
Deidentified clinical data (case histories and clinical information) and variant
data (exempt from IRB review) for probands or families who could not be
contacted was used, and research conformed to the Helsinki Declaration.
Probands or their families were contacted directly and consented by the
University of Washington Autism Center under the TIGER study (IRB#:
STUDY00000813), which includes consent for age and sex to be published.
Competing interests
The Department of Molecular and Human Genetics at Baylor College of Medicine
receives revenue from clinical genetic testing conducted at Baylor Genetics Laboratory.
E.T. is an employee of GeneDx. The remaining authors declare no competing interests.
Author details
1Department of Genome Sciences, University of Washington School of
Medicine, 3720 15th Ave NE S413A, Box 355065, Seattle, WA 981095-5065,
USA. 2Baylor Genetics Laboratories, Houston, TX, USA. 3Department of
Molecular & Human Genetics, Baylor College of Medicine, Houston, TX, USA.
4Center for Medical Genetics and Hunan Key Laboratory of Medical Genetics,
School of Life Sciences, Central South University, Changsha, Hunan, China.
5Department of Anatomy, University of California, San Francisco, CA, USA.
6Department of Psychiatry, University of California, San Francisco, CA, USA.
7Weill Institute for Neurosciences, University of California at San Francisco,
San Francisco, CA, USA. 8The Eli and Edythe Broad Center of Regeneration
Medicine and Stem Cell Research, University of California, San Francisco, CA,
USA. 9Department of Human Genetics, Radboud University Medical Center,
Nijmegen, The Netherlands. 10Department of Molecular Medicine and
Surgery, Center for Molecular Medicine, Karolinska Institutet, Stockholm,
Sweden. 11Department of Clinical Genetics, Karolinska University Hospital,
Stockholm, Sweden. 12School of Medicine and the Robinson Research
Institute, the University of Adelaide at the Women’s and Children’s Hospital,
Adelaide, South Australia, Australia. 13Genetics and Molecular Pathology, SA
Pathology, Adelaide, South Australia, Australia. 14South Australian Health and
Medical Research Institute, Adelaide, South Australia, Australia. 15Laboratorio
di Genetica Medica - ASST Papa Giovanni XXIII, Bergamo, Italy. 16Department
of Pediatrics, ASST Papa Giovanni XXIII, Bergamo, Italy. 17Genetic Unit,
Department of Pediatrics, Fondazione MBBM S. Gerardo Hospital, Monza,
Gillentine et al. Genome Medicine           (2021) 13:63 Page 22 of 26
Content courtesy of Springer Nature, terms of use apply. Rights reserved.
Italy. 18Unit of Neuromuscular and Neurodegenerative Disorders, Department
Neurosciences, Bambino Gesù Children’s Hospital, IRCCS, 00146 Rome, Italy.
19Institute of Human Genetics, Friedrich-Alexander-Universität
Erlangen-Nürnberg (FAU), Erlangen, Germany. 20Center on Human
Development and Disability, University of Washington, Seattle, WA, USA.
21Seattle Children’s Autism Center, Seattle, WA, USA. 22GeneDX, Gaithersburg,
MD, USA. 23Department of Pediatrics-Neurology, Baylor College of Medicine,
Houston, TX, USA. 24Texas Children’s Hospital, Houston, TX, USA.
25Department of Neurology, Boston Children’s Hospital, Harvard Medical
School, Boston, MA, USA. 26The Atwal Clinic: Genomic & Personalized
Medicine, Jacksonville, FL, USA. 27Department of Pediatrics, Section of
Genetics, University of Illinois at Chicago, Chicago, IL, USA. 28Department of
Pediatrics, University of California San Diego, San Diego, CA, USA. 29Genetics/
Dysmorphology, Rady Children’s Hospital San Diego, San Diego, CA, USA.
30Rady Children’s Institute for Genomic Medicine, San Diego, CA, USA.
31Department of Neurosciences, University of California San Diego, San
Diego, CA, USA. 32Department of Biomolecular Medicine, Ghent University
Hospital, Ghent, Belgium. 33Clinique de Génétique, Hôpital Jeanne de
Flandre, Bâtiment Modulaire, CHU, 59037 Lille Cedex, France. 34Sorbonne
Universités, Centre de Référence déficiences intellectuelles de causes rares,
département de génétique et embryologie médicale, Hôpital Trousseau,
AP-HP, Paris, France. 35Department of Pediatrics, Indiana University School of
Medicine, Indianapolis, IN, USA. 36Department of Medical and Molecular
Genetics, IU Health, Indianapolis, IN, USA. 37Department of Genetics,
Hadassah, Hebrew University Medical Center, Jerusalem, Israel. 38Pediatric
Neurology, Assuta-Ashdod University Hospital, Ashdod, Israel. 39Health
Sciences, Ben-Gurion University of the Negev, Beersheba, Israel.
40Department of Clinical Genetics, Odense University Hospital, Odense,
Denmark. 41H C Andersen Chilldrens Hospital, Odense University Hospital,
Odense, Denmark. 42Gillette Children’s Specialty Healthcare, Saint Paul, MN,
USA. 43Division of Clinical Genetics, Children’s Mercy Kansas City, Kansas City,
MO, USA. 44The University of Missouri-Kansas City, School of Medicine, Kansas
City, MO, USA. 45Children’s Mercy Kansas City, Center for Pediatric Genomic
Medicine, Kansas City, MO, USA. 46Oregon Health & Science University,
Corvallis, OR, USA. 47Department of Genetics, Hópital Pitié-Salpêtrière, Paris,
France. 48Department of Medical Genetics, University of Antwerp, Antwerp,
Belgium. 49Genetics Department, Cook Children’s Hospital, Fort Worth, TX,
USA. 50Department of Medical Genetics, University of British Columbia,
Vancouver, Canada. 51BC Children’s Hospital and BC Women’s Hospital,
Vancouver, BC, Canada. 52Division of Developmental Pediatrics, Department
of Pediatrics, BC Children’s Hospital, University of British Columbia,
Vancouver, BC, Canada. 53Sunny Hill Health Centre for Children, Vancouver,
BC, Canada. 54Department of Pediatrics, The Children’s Hospital at
Montefiore, Bronx, NY, USA. 55Institute of Human Genetics, University Medical
Center Hamburg-Eppendorf, Hamburg, Germany. 56Department of Human
Genetics, University of Pittsburgh, Pittsburgh, PA, USA. 57UPMC Children’s
Hospital of Pittsburgh, Pittsburgh, PA, USA. 58Kaiser Permanente Southern
California, Los Angeles, CA, USA. 59The Permanente Medical Group, Oakland,
CA, USA. 60Northern Ireland Regional Genetics Service, Belfast City Hospital,
Belfast, UK. 61Center for Integrative Brain Research, Seattle Children’s
Research Institute, Seattle, WA, USA. 62Department of Pediatrics, University of
Washington, Seattle, WA, USA. 63Brotman Baty Institute for Precision
Medicine, Seattle, WA, USA. 64Al Dupont Hospital for Children, Wilmington,
DE, USA. 65NYU Grossman School of Medicine, Department of Pediatrics,
Clinical Genetic Services, New York, NY, USA. 66Center for Human Genetics,
KU Leuven and Leuven Autism Research (LAuRes), Leuven, Belgium. 67Oasi
Research Institute-IRCCS, Troina, Italy. 68Department of Genetics, University
Medical Center, Utrecht University, Utrecht, The Netherlands. 69Rare Disease
Institute, Children’s National Health System, Washington, DC, USA.
70Department of Genetics, Driscoll Children’s Hospital, Corpus Christi, TX,
USA. 71Department of Pediatric Gastroenterology, Driscoll Children’s Hospital,
Corpus Christi, TX, USA. 72Àrea de Genètica Clínica i Molecular, Hospital Vall
d’Hebrón, Barcelona, Spain. 73Centre de référence Anomalies du
développement, CHU Grenoble-Alpes, Grenoble, France. 74UF Innovation en
Diagnostic Génomique des Maladies Rares, FHU-TRANSLAD, CHU Dijon
Bourgogne and INSERM UMR1231 GAD, Université de Bourgogne
Franche-Comté, F-21000 Dijon, France. 75INSERM UMR 1231 Génétique des
Anomalies du Développement, Université Bourgogne Franche-Comté, Dijon,
France. 76Centre de Référence Maladies Rares « déficience intellectuelle »,
Centre de Génétique, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.
77Centre de Référence Maladies Rares « Anomalies du Développement et
Syndromes malformatifs » Université Bourgogne Franche-Comté, Dijon,
France. 78Department of Psychiatry and Behavioral Sciences, University of
Washington, Seattle, WA, USA. 79Howard Hughes Medical Institute, University
of Washington, Seattle, WA, USA.
Received: 4 September 2020 Accepted: 16 March 2021
References
1. Coe BP, Stessman HAF, Sulovari A, Geisheker MR, Bakken TE, Lake AM, et al.
Neurodevelopmental disease genes implicated by de novo mutation and
copy number variation morbidity. Nat Genet. 2019;51(1):106–16.
2. Khalil B, Morderer D, Price PL, Liu F, Rossoll W. mRNP assembly, axonal
transport, and local translation in neurodegenerative diseases. Brain Res.
2018;1693(Pt A):75–91.
3. Purice MD, Taylor JP. Linking hnRNP function to ALS and FTD pathology.
Front Neurosci. 2018;12
4. Fu X-D, Ares M. Context-dependent control of alternative splicing by RNA-
binding proteins. Nat Rev Genet. 2014;15(10):689–701.
5. Dickerson JE, Robertson DL. On the origins of Mendelian disease genes in
man: the impact of gene duplication. Mol Biol Evol. 2012;29(1):61–9.
6. Chen W-H, Zhao X-M, van Noort V, Bork P. Human monogenic disease
genes have frequently functionally redundant paralogs. PLoS Comput Biol.
2013;16:9(5).
7. Lal D, May P, Perez-Palma E, Samocha KE, Kosmicki JA, Robinson EB, et al.
Gene family information facilitates variant interpretation and identification
of disease-associated genes in neurodevelopmental disorders. Genome
Med. 2020;12(1):1–12.
8. Kim HJ, Kim NC, Wang Y-D, Scarborough EA, Moore J, Diaz Z, et al.
Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause
multisystem proteinopathy and ALS. Nature. 2013;495(7442):467–73.
9. Le Ber I, Van Bortel I, Nicolas G, Bouya-Ahmed K, Camuzat A, Wallon D, et al.
hnRNPA2B1 and hnRNPA1 mutations are rare in patients with “multisystem
proteinopathy” and frontotemporal lobar degeneration phenotypes.
Neurobiol Aging. 2014;35(4):934.e5–934.e6.
10. Bhoj E, Halbach S, McDonald-McGinn D, Tan C, Lande R, Waggoner D, et al.
Expanding the spectrum of microdeletion 4q21 syndrome: a partial
phenotype with incomplete deletion of the minimal critical region and a
new association with cleft palate and Pierre Robin sequence. Am J Med
Genet A. 2013;161(9):2327–33.
11. Reichert SC, Li R, Turner SA, van Jaarsveld RH, Massink MPG, van den
Boogaard M-JH, et al. HNRNPH1-related syndromic intellectual disability:
seven additional cases suggestive of a distinct syndromic
neurodevelopmental syndrome. Clin Genet. 2020;98(1):91–8.
12. Bain JM, Cho MT, Telegrafi A, Wilson A, Brooks S, Botti C, et al. Variants in
HNRNPH2 on the X chromosome are associated with a
neurodevelopmental disorder in females. Am J Hum Genet. 2016;99(3):728–
34.
13. Au PYB, Goedhart C, Ferguson M, Breckpot J, Devriendt K, Wierenga K, et al.
Phenotypic spectrum of Au-Kline syndrome: a report of six new cases and
review of the literature. Eur J Hum Genet EJHG. 2018;26(9):1272–81.
14. Okamoto N. Okamoto syndrome has features overlapping with Au-Kline
syndrome and is caused by HNRNPK mutation. Am J Med Genet A. 2019;
179(5):822–6.
15. Dentici ML, Barresi S, Niceta M, Pantaleoni F, Pizzi S, Dallapiccola B, et al.
Clinical spectrum of Kabuki-like syndrome caused by HNRNPK
haploinsufficiency. Clin Genet. 2018;93(2):401–7.
16. Lange L, Pagnamenta AT, Lise S, Clasper S, Stewart H, Akha ES, et al. A de
novo frameshift in HNRNPK causing a Kabuki-like syndrome with nodular
heterotopia. Clin Genet. 2016;90(3):258–62.
17. Miyake N, Inaba M, Mizuno S, Shiina M, Imagawa E, Miyatake S, Nakashima
M, Mizuguchi T, Takata A, Ogata K, Matsumoto N A case of atypical kabuki
syndrome arising from a novel missense variant in HNRNPK. Clin Genet.
2017;92(5):554–5.
18. Duijkers FA, McDonald A, Janssens GE, Lezzerini M, Jongejan A, van
Koningsbruggen S, et al. HNRNPR variants that impair Homeobox gene expression
drive developmental disorders in humans. Am J Hum Genet. 2019;104(6):1040–59.
19. Engwerda A, Frentz B, den Ouden AL, Flapper BCT, Swertz MA, Gerkes EH, et al. The
phenotypic spectrum of proximal 6q deletions based on a large cohort derived
from social media and literature reports. Eur J Hum Genet. 2018;26(10):1478–89.
Gillentine et al. Genome Medicine           (2021) 13:63 Page 23 of 26
Content courtesy of Springer Nature, terms of use apply. Rights reserved.
20. Depienne C, Nava C, Keren B, Heide S, Rastetter A, Passemard S, et al.
Genetic and phenotypic dissection of 1q43q44 microdeletion syndrome
and neurodevelopmental phenotypes associated with mutations in ZBTB18
and HNRNPU. Hum Genet. 2017;136(4):463–79.
21. Yates TM, Vasudevan PC, Chandler KE, Donnelly DE, Stark Z, Sadedin S,
Willoughby J, Broad Center for Mendelian Genomics, DDD study,
Balasubramanian M. De novo mutations in HNRNPU result in a
neurodevelopmental syndrome. Am J Med Genet A. 2017;173(11):3003–12.
22. Bramswig NC, Lüdecke H-J, Hamdan FF, Altmüller J, Beleggia F, Elcioglu NH,
et al. Heterozygous HNRNPU variants cause early onset epilepsy and severe
intellectual disability. Hum Genet. 2017;136(7):821–34.
23. Leduc MS, Chao H-T, Qu C, Walkiewicz M, Xiao R, Magoulas P, et al. Clinical
and molecular characterization of de novo loss of function variants in HNRN
PU. Am J Med Genet A. 2017;173(10):2680–9.
24. Turner TN, Yi Q, Krumm N, Huddleston J, Hoekzema K, F Stessman HA, et al.
denovo-db: a compendium of human de novo variants. Nucleic Acids Res.
2017;45(D1):D804–11.
25. Harmsen S, Buchert R, Mayatepek E, Haack TB, Distelmaier F. Bain type of X-
linked syndromic mental retardation in boys. Clin Genet. 2019;95(6):734–5.
26. Jepsen WM, Ramsey K, Szelinger S, Llaci L, Balak C, Belnap N, Bilagody C, de
Both M, Gupta R, Naymik M, Pandey R, Piras IS, Sanchez-Castillo M,
Rangasamy S, Narayanan V, Huentelman MJ. Two additional males with X-
linked, syndromic mental retardation carry de novo mutations in HNRNPH2.
Clin Genet. 2019;96(2):183–5.
27. Pilch J, Koppolu AA, Walczak A, Murcia Pienkowski VA, Biernacka A, Skiba P,
et al. Evidence for HNRNPH1 being another gene for Bain type syndromic
mental retardation. Clin Genet. 2018;94(3–4):381–5.
28. Somashekar PH, Narayanan DL, Jagadeesh S, Suresh B, Vaishnavi RD, Bielas
S, et al. Bain type of X-linked syndromic mental retardation in a male with a
pathogenic variant in HNRNPH2. Am J Med Genet A. 2020;182(1):183–8.
29. denovo-db. Available from: http://denovo-db.gs.washington.edu
30. Durkin A, Albaba S, Fry AE, Morton JE, Douglas A, Beleza A, Williams D,
Volker-Touw CML, Lynch SA, Canham N, Clowes V, Straub V, Lachlan K,
Gibbon F, el Gamal M, Varghese V, Parker MJ, Newbury-Ecob R, Turnpenny
PD, Gardham A, Ghali N, Balasubramanian M. Clinical findings of 21
previously unreported probands with HNRNPU-related syndrome and
comprehensive literature review. Am J Med Genet A. 2020;182(7):1637–54.
31. Caliebe A, Kroes HY, van der Smagt JJ, Martin-Subero JI, Tönnies H, Van ‘t
Slot R, et al. Four patients with speech delay, seizures and variable corpus
callosum thickness sharing a 0.440 Mb deletion in region 1q44 containing
the HNRPU gene. Eur J Med Genet. 2010;53(4):179–85.
32. de Kovel CGF, Brilstra EH, van Kempen MJA, Van’t Slot R, Nijman IJ, Afawi Z,
et al. Targeted sequencing of 351 candidate genes for epileptic
encephalopathy in a large cohort of patients. Mol Genet Genomic Med.
2016;4(5):568–80.
33. Demos M, Guella I, DeGuzman C, McKenzie MB, Buerki SE, Evans DM, et al.
Diagnostic yield and treatment impact of targeted exome sequencing in
early-onset epilepsy. Front Neurol. 2019;10:434.
34. Stessman HAF, Xiong B, Coe BP, Wang T, Hoekzema K, Fenckova M,
Kvarnung M, Gerdts J, Trinh S, Cosemans N, Vives L, Lin J, Turner TN, Santen
G, Ruivenkamp C, Kriek M, van Haeringen A, Aten E, Friend K, Liebelt J,
Barnett C, Haan E, Shaw M, Gecz J, Anderlid BM, Nordgren A, Lindstrand A,
Schwartz C, Kooy RF, Vandeweyer G, Helsmoortel C, Romano C, Alberti A,
Vinci M, Avola E, Giusto S, Courchesne E, Pramparo T, Pierce K, Nalabolu S,
Amaral DG, Scheffer IE, Delatycki MB, Lockhart PJ, Hormozdiari F, Harich B,
Castells-Nobau A, Xia K, Peeters H, Nordenskjöld M, Schenck A, Bernier RA,
Eichler EE. Targeted sequencing identifies 91 neurodevelopmental-disorder
risk genes with autism and developmental-disability biases. Nat Genet. 2017;
49(4):515–26.
35. De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, et al.
Synaptic, transcriptional and chromatin genes disrupted in autism. Nature.
2014;515(7526):209–15.
36. Yuen RK, Merico D, Bookman M, L Howe J, Thiruvahindrapuram B, Patel RV,
et al. Whole genome sequencing resource identifies 18 new candidate
genes for autism spectrum disorder. Nat Neurosci 2017;20(4):602–611.
37. Krumm N, Turner TN, Baker C, Vives L, Mohajeri K, Witherspoon K, Raja A,
Coe BP, Stessman HA, He ZX, Leal SM, Bernier R, Eichler EE. Excess of rare,
inherited truncating mutations in autism. Nat Genet. 2015;47(6):582–8.
38. Lelieveld SH, Reijnders MRF, Pfundt R, Yntema HG, Kamsteeg E-J, de Vries P,
et al. Meta-analysis of 2,104 trios provides support for 10 new genes for
intellectual disability. Nat Neurosci. 2016;19(9):1194–6.
39. Epi4K Consortium, Epilepsy Phenome/Genome Project, Allen AS, Berkovic
SF, Cossette P, Delanty N, et al. De novo mutations in epileptic
encephalopathies. Nature. 2013;501(7466):217–21.
40. Hinokuma N, Nakashima M, Asai H, Nakamura K, Akaboshi S, Fukuoka M,
et al. Clinical and genetic characteristics of patients with Doose syndrome.
Epilepsia Open.
41. Helbig KL, Farwell Hagman KD, Shinde DN, Mroske C, Powis Z, Li S, et al.
Diagnostic exome sequencing provides a molecular diagnosis for a
significant proportion of patients with epilepsy. Genet Med Off J Am Coll
Med Genet. 2016;18(9):898–905.
42. Feliciano P, Zhou X, Astrovskaya I, Turner TN, Wang T, Brueggeman L, et al.
Exome sequencing of 457 autism families recruited online provides
evidence for autism risk genes. NPJ Genomic Med. 2019;4(1):19.
43. Yamada M, Shiraishi Y, Uehara T, Suzuki H, Takenouchi T, Abe-Hatano C,
et al. Diagnostic utility of integrated analysis of exome and transcriptome:
successful diagnosis of Au-Kline syndrome in a patient with submucous
cleft palate, scaphocephaly, and intellectual disabilities. Mol Genet Genomic
Med. 2020;8(9):e1364.
44. Peron A, Novara F, Briola FL, Merati E, Giannusa E, Segalini E, et al. Missense
variants in the Arg206 residue of HNRNPH2: further evidence of causality
and expansion of the phenotype. Am J Med Genet A. 2020;182(4):823–8.
45. Borlot F, de Almeida BI, Combe SL, Andrade DM, Filloux FM, Myers KA.
Clinical utility of multigene panel testing in adults with epilepsy and
intellectual disability. Epilepsia. 2019;60(8):1661–9.
46. Carvill GL, Heavin SB, Yendle SC, McMahon JM, O’Roak BJ, Cook J, et al.
Targeted resequencing in epileptic encephalopathies identifies de novo
mutations in CHD2 and SYNGAP1. Nat Genet. 2013;45(7):825–30.
47. Chérot E, Keren B, Dubourg C, Carré W, Fradin M, Lavillaureix A, et al. Using
medical exome sequencing to identify the causes of neurodevelopmental
disorders: experience of 2 clinical units and 216 patients. Clin Genet. 2018;
93(3):567–76.
48. Coppola A, Cellini E, Stamberger H, Saarentaus E, Cetica V, Lal D, et al.
Diagnostic implications of genetic copy number variation in epilepsy plus.
Epilepsia. 2019;60(4):689–706.
49. The Epilepsy Genetics Initiative. Systematic reanalysis of diagnostic exomes
increases yield. Epilepsia. 2019;60(5):797–806.
50. Hamdan FF, Srour M, Capo-Chichi J-M, Daoud H, Nassif C, Patry L, et al. De
novo mutations in moderate or severe intellectual disability. PLoS Genet.
2014;10(10):e1004772.
51. Johannesen KM, Nikanorova N, Marjanovic D, Pavbro A, Larsen LHG, Rubboli
G, et al. Utility of genetic testing for therapeutic decision-making in adults
with epilepsy. Epilepsia. 2020;61(6):1234–9.
52. Mignot C, von Stülpnagel C, Nava C, Ville D, Sanlaville D, Lesca G, et al.
Genetic and neurodevelopmental spectrum of SYNGAP1-associated
intellectual disability and epilepsy. J Med Genet. 2016;53(8):511–22.
53. Monroe GR, Frederix GW, Savelberg SMC, de Vries TI, Duran KJ, van der
Smagt JJ, et al. Effectiveness of whole-exome sequencing and costs of the
traditional diagnostic trajectory in children with intellectual disability. Genet
Med Off J Am Coll Med Genet. 2016;18(9):949–56.
54. Oates S, Tang S, Rosch R, Lear R, Hughes EF, Williams RE, et al. Incorporating
epilepsy genetics into clinical practice: a 360°evaluation. Npj Genomic Med.
2018;3(1):1–11.
55. Pinto D, Delaby E, Merico D, Barbosa M, Merikangas A, Klei L, et al.
Convergence of genes and cellular pathways dysregulated in autism
spectrum disorders. Am J Hum Genet. 2014;94(5):677–94.
56. Stamouli S, Anderlid B-M, Willfors C, Thiruvahindrapuram B, Wei J, Berggren
S, et al. Copy number variation analysis of 100 twin pairs enriched for
neurodevelopmental disorders. Twin Res Hum Genet. 2018;21(1):1–11.
57. Zhu X, Petrovski S, Xie P, Ruzzo EK, Lu Y-F, McSweeney KM, et al. Whole-
exome sequencing in undiagnosed genetic diseases: interpreting 119 trios.
Genet Med Off J Am Coll Med Genet. 2015;17(10):774–81.
58. Deciphering Developmental Disorders Study. Prevalence and architecture of
de novo mutations in developmental disorders. Nature. 2017;542(7642):433–8.
59. Maystadt I, Deprez M, Moortgat S, Benoît V, Karadurmus D. A second case
of Okamoto syndrome caused by HNRNPK mutation. Am J Med Genet A.
2020;182(6):1537–9.
60. Shimada S, Oguni H, Otani Y, Nishikawa A, Ito S, Eto K, Nakazawa T,
Yamamoto-Shimojima K, Takanashi JI, Nagata S, Yamamoto T. An episode of
acute encephalopathy with biphasic seizures and late reduced diffusion
followed by hemiplegia and intractable epilepsy observed in a patient with
a novel frameshift mutation in HNRNPU. Brain Dev. 2018;40(9):813–8.
Gillentine et al. Genome Medicine           (2021) 13:63 Page 24 of 26
Content courtesy of Springer Nature, terms of use apply. Rights reserved.
61. Wang T, Hoekzema K, Vecchio D, Wu H, Sulovari A, Coe BP, et al. Large-scale
targeted sequencing identifies risk genes for neurodevelopmental disorders.
Nat Commun. 2020;11(1):4932.
62. Kaplanis J, Samocha KE, Wiel L, Zhang Z, Arvai KJ, Eberhardt RY, et al.
Evidence for 28 genetic disorders discovered by combining healthcare and
research data. Nature. 2020;586(7831):757–62.
63. Satterstrom FK, Kosmicki JA, Wang J, Breen MS, De Rubeis S, An J-Y, et al.
Large-scale exome sequencing study implicates both developmental and
functional changes in the neurobiology of autism. Cell. 2020;180(3):568–84. e23
64. Iourov IY, Zelenova MA, Vorsanova SG, Voinova VV, Yurov YB. 4q21.2q21.3
duplication: molecular and neuropsychological aspects. Curr Genomics.
2018;19(3):173–8.
65. Lebedev IN, Nazarenko LP, Skryabin NA, Babushkina NP, Kashevarova AA. A
de novo microtriplication at 4q21.21-q21.22 in a patient with a vascular
malignant hemangioma, elongated sigmoid colon, developmental delay,
and absence of speech. Am J Med Genet A. 2016;170(8):2089–96.
66. Zarrei M, Merico D, Kellam B, Engchuan W, Scriver T, Jokhan R, Wilson MD,
Parr J, Lemire EG, Stavropoulos DJ, Scherer SW. A de novo deletion in a boy
with cerebral palsy suggests a refined critical region for the 4q21.22
microdeletion syndrome. Am J Med Genet A. 2017;173(5):1287–93.
67. Mohamed AM, El-Bassyouni HT, El-Gerzawy AM, Hammad SA, Helmy NA,
Kamel AK, et al. Cytogenomic characterization of 1q43q44 deletion
associated with 4q32.1q35.2 duplication and phenotype correlation. Mol
Cytogenet. 2018;11:57.
68. Stessman HA, Bernier R, Eichler EE. A genotype-first approach to defining
the subtypes of a complex disease. Cell. 2014;156(5):872–7.
69. Yang Y, Muzny DM, Xia F, Niu Z, Person R, Ding Y, et al. Molecular findings among
patients referred for clinical whole-exome sequencing. JAMA. 2014;312(18):1870–9.
70. Garrison E, Marth G. Haplotype-based variant detection from short-read
sequencing. ArXiv:12073907 [q-bio.GN] 2012. https://arxiv.org/abs/1207.3907.
71. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al.
The genome analysis toolkit: a MapReduce framework for analyzing next-
generation DNA sequencing data. Genome Res. 2010;20(9):1297–303.
72. Danecek P, McCarthy SA. BCFtools/csq: haplotype-aware variant
consequences. Bioinformatics. 2017;33(13):2037–9.
73. Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching
tool for connecting investigators with an interest in the same gene. Hum
Mutat. 2015;36(10):928–30.
74. NHGRI/NHLBI University of Washington-Center for Mendelian Genomics
(UW-CMG), Seattle, WA. MyGene2. Available from: http://www.mygene2.org
75. Abramovs N, Brass A, Tassabehji M. GeVIR is a continuous gene-level metric
that uses variant distribution patterns to prioritize disease candidate genes.
Nat Genet. 2020;52(1):35–9.
76. O’Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP, et al. Sporadic
autism exomes reveal a highly interconnected protein network of de novo
mutations. Nature. 2012;485(7397):246–50.
77. Samocha KE, Robinson EB, Sanders SJ, Stevens C, Sabo A, McGrath LM, et al.
A framework for the interpretation of de novo mutation in human disease.
Nat Genet. 2014;46(9):944–50.
78. Wiel L, Baakman C, Gilissen D, Veltman JA, Vriend G, Gilissen C. MetaDome:
Pathogenicity analysis of genetic variants through aggregation of
homologous human protein domains. Hum Mutat. 2019;40(8):1030–8.
79. Meyer MJ, Beltrán JF, Liang S, Fragoza R, Rumack A, Liang J, et al.
Interactome INSIDER: a structural interactome browser for genomic studies.
Nat Methods. 2018;15(2):107–14.
80. Turner TN, Douville C, Kim D, Stenson PD, Cooper DN, Chakravarti A, Karchin
R. Proteins linked to autosomal dominant and autosomal recessive disorders
harbor characteristic rare missense mutation distribution patterns. Hum Mol
Genet. 2015;24(21):5995–6002.
81. Coban-Akdemir Z, White JJ, Song X, Jhangiani SN, Fatih JM, Gambin T, et al.
Identifying genes whose mutant transcripts cause dominant disease traits
by potential gain-of-function alleles. Am J Hum Genet. 2018;103(2):171–87.
82. Shamsani J, Kazakoff SH, Armean IM, McLaren W, Parsons MT, Thompson
BA, O’Mara TA, Hunt SE, Waddell N, Spurdle AB. A plugin for the Ensembl
variant effect predictor that uses MaxEntScan to predict variant
spliceogenicity. Bioinformatics. 2019;35(13):2315–7.
83. Geuens T, Bouhy D, Timmerman V. The hnRNP family: insights into their role
in health and disease. Hum Genet. 2016;135(8):851–67.
84. Nowakowski TJ, Bhaduri A, Pollen AA, Alvarado B, Mostajo-Radji MA, Di Lullo
E, et al. Spatiotemporal gene expression trajectories reveal developmental
hierarchies of the human cortex. Science. 2017;358(6368):1318–23.
85. CSEA tool. Available from: http://genetics.wustl.edu/jdlab/csea-tool-2/
86. Babbi G, Martelli PL, Casadio R. PhenPath: a tool for characterizing biological
functions underlying different phenotypes. BMC Genomics. 2019;20(8):548.
87. gnomAD. Available from: https://gnomad.broadinstitute.org/
88. Huelga SC, Vu AQ, Arnold JD, Liang TY, Liu PP, Yan BY, et al. Integrative
genome-wide analysis reveals cooperative regulation of alternative splicing
by hnRNP proteins. Cell Rep. 2012;1(2):167–78.
89. Cooper-Knock J, Higginbottom A, Stopford MJ, Highley JR, Ince PG,
Wharton SB, Pickering-Brown S, Kirby J, Hautbergue GM, Shaw PJ. Antisense
RNA foci in the motor neurons of C9ORF72-ALS patients are associated with
TDP-43 proteinopathy. Acta Neuropathol (Berl). 2015;130(1):63–75.
90. Mohagheghi F, Prudencio M, Stuani C, Cook C, Jansen-West K, Dickson DW,
Petrucelli L, Buratti E. TDP-43 functions within a network of hnRNP proteins
to inhibit the production of a truncated human SORT1 receptor. Hum Mol
Genet. 2016;25(3):534–45.
91. Kashima T, Rao N, David CJ, Manley JL. hnRNP A1 functions with specificity in
repression of SMN2 exon 7 splicing. Hum Mol Genet. 2007;16(24):3149–59.
92. Berson A, Barbash S, Shaltiel G, Goll Y, Hanin G, Greenberg DS, et al.
Cholinergic-associated loss of hnRNP-A/B in Alzheimer’s disease impairs
cortical splicing and cognitive function in mice. EMBO Mol Med. 2012;4(8):
730–42.
93. Borreca A, Gironi K, Amadoro G, Ammassari-Teule M. Opposite
dysregulation of fragile-X mental retardation protein and heteronuclear
ribonucleoprotein C protein associates with enhanced APP translation in
Alzheimer disease. Mol Neurobiol. 2016;53(5):3227–34.
94. Sun Y, Chen H, Lu Y, Duo J, Lei L, OuYang Y, et al. Limb girdle muscular
dystrophy D3 HNRNPDL related in a Chinese family with distal muscle
weakness caused by a mutation in the prion-like domain. J Neurol. 2019;
266(2):498–506.
95. Mori K, Lammich S, Mackenzie IRA, Forné I, Zilow S, Kretzschmar H, et al.
hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/
TDP43-negative inclusions in the hippocampus of patients with C9orf72
mutations. Acta Neuropathol (Berl). 2013;125(3):413–23.
96. Lee EK, Kim HH, Kuwano Y, Abdelmohsen K, Srikantan S, Subaran SS, et al.
hnRNP C promotes APP translation by competing with FMRP for APP mRNA
recruitment to P bodies. Nat Struct Mol Biol. 2010;17(6):732–9.
97. Moursy A, Allain FH-T, Cléry A. Characterization of the RNA recognition
mode of hnRNP G extends its role in SMN2 splicing regulation. Nucleic
Acids Res. 2014;42(10):6659–72.
98. Barbash S, Garfinkel BP, Maoz R, Simchovitz A, Nadorp B, Guffanti A, et al.
Alzheimer’s brains show inter-related changes in RNA and lipid metabolism.
Neurobiol Dis. 2017;106:1–13.
99. Cho S, Moon H, Loh TJ, Oh HK, Cho S, Choy HE, et al. hnRNP M facilitates exon
7 inclusion of SMN2 pre-mRNA in spinal muscular atrophy by targeting an
enhancer on exon 7. Biochim Biophys Acta. 2014;1839(4):306–15.
100. Waibel S, Neumann M, Rabe M, Meyer T, Ludolph AC. Novel missense and
truncating mutations in FUS/TLS in familial ALS. Neurology. 2010;75(9):815–7.
101. Vance C, Rogelj B, Hortobágyi T, De Vos KJ, Nishimura AL, Sreedharan J,
et al. Mutations in FUS, an RNA processing protein, cause familial
amyotrophic lateral sclerosis type 6. Science. 2009;323(5918):1208–11.
102. Chen H-H, Chang J-G, Lu R-M, Peng T-Y, Tarn W-Y. The RNA binding protein
hnRNP Q modulates the utilization of exon 7 in the survival motor neuron 2
(SMN2) gene. Mol Cell Biol. 2008;28(22):6929–38.
103. Dombert B, Sivadasan R, Simon CM, Jablonka S, Sendtner M. Presynaptic
localization of Smn and hnRNP R in axon terminals of embryonic and
postnatal mouse motoneurons. PLoS One. 2014;9(10):e110846.
104. Guo H, Duyzend MH, Coe BP, Baker C, Hoekzema K, Gerdts J, et al. Genome
sequencing identifies multiple deleterious variants in autism patients with
more severe phenotypes. Genet Med. 2019;21(7):1611–1620. A.
105. Iossifov I, O’Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, et al. The
contribution of de novo coding mutations to autism spectrum disorder.
Nature. 2014;515(7526):216–21.
106. Rauch A, Wieczorek D, Graf E, Wieland T, Endele S, Schwarzmayr T, et al.
Range of genetic mutations associated with severe non-syndromic sporadic
intellectual disability: an exome sequencing study. Lancet Lond Engl. 2012;
380(9854):1674–82.
107. Ernst C. Proliferation and differentiation deficits are a major convergence
point for neurodevelopmental disorders. Trends Neurosci. 2016 [cited 2020
Feb 12];39(5):290–9.
108. Donovan APA, Basson MA. The neuroanatomy of autism – a developmental
perspective. J Anat. 2017;230(1):4–15.
Gillentine et al. Genome Medicine           (2021) 13:63 Page 25 of 26
Content courtesy of Springer Nature, terms of use apply. Rights reserved.
109. Guarnieri FC, de Chevigny A, Falace A, Cardoso C. Disorders of neurogenesis
and cortical development. Dialogues Clin Neurosci. 2018;20(4):255–66.
110. Wang Y-C, Chang K-C, Lin B-W, Lee J-C, Lai C-H, Lin L-J, et al. The EGF/
hnRNP Q1 axis is involved in tumorigenesis via the regulation of cell cycle-
related genes. Exp Mol Med. 2018;50(6):70.
111. Chun Y, Kim R, Lee S. Centromere protein (CENP)-W interacts with
heterogeneous nuclear ribonucleoprotein (hnRNP) U and may contribute to
kinetochore-microtubule attachment in mitotic cells. PLoS One. 2016;11(2):
e0149127.
112. Douglas P, Ye R, Morrice N, Britton S, Trinkle-Mulcahy L, Lees-Miller SP.
Phosphorylation of SAF-A/hnRNP-U serine 59 by Polo-like kinase 1 is
required for mitosis. Mol Cell Biol. 2015;35(15):2699–713.
113. Sugimasa H, Taniue K, Kurimoto A, Takeda Y, Kawasaki Y, Akiyama T.
Heterogeneous nuclear ribonucleoprotein K upregulates the kinetochore
complex component NUF2 and promotes the tumorigenicity of colon
cancer cells. Biochem Biophys Res Commun. 2015;459(1):29–35.
114. Al-Khalaf HH, Colak D, Al-Saif M, Al-Bakheet A, Hendrayani S-F, Al-Yousef N,
et al. p16INK4A positively regulates Cyclin D1 and E2F1 through negative
control of AUF1. PLoS One. 2011;6(7):e21111.
115. Schuetze M, Park MTM, Cho IY, MacMaster FP, Chakravarty MM, Bray
SL. Morphological alterations in the thalamus, striatum, and pallidum
in autism spectrum disorder. Neuropsychopharmacology. 2016;41(11):
2627–37.
116. Peixoto RT, Chantranupong L, Hakim R, Levasseur J, Wang W, Merchant T,
et al. Abnormal striatal development underlies the early onset of behavioral
deficits in Shank3B−/− mice. Cell Rep. 2019;29(7):2016–27. e4
117. Schumann CM, Bauman MD, Amaral DG. Abnormal structure or function of
the amygdala is a common component of neurodevelopmental disorders.
Neuropsychologia. 2011;49(4):745–59.
118. Pérez-Palma E, May P, Iqbal S, Niestroj L-M, Du J, Heyne HO, et al.
Identification of pathogenic variant enriched regions across genes and
gene families. Genome Res. 2020;30(1):62–71.
119. Dusen CMV, Yee L, McNally LM, McNally MT. A glycine-rich domain of
hnRNP H/F promotes nucleocytoplasmic shuttling and nuclear import
through an interaction with transportin 1. Mol Cell Biol. 2010;30(10):2552–
62.
120. Choi J-H, Kim S-H, Jeong Y-H, Kim SW, Min K-T, Kim K-T. hnRNP Q regulates
internal ribosome entry site-mediated fmr1 translation in neurons. Mol Cell
Biol. 2019;39(4):e00371–18.
121. Tratnjek L, Živin M, Glavan G. Synaptotagmin 7 and SYNCRIP proteins are
ubiquitously expressed in the rat brain and co-localize in Purkinje neurons. J
Chem Neuroanat. 2017;79:12–21.
122. Williams KR, McAninch DS, Stefanovic S, Xing L, Allen M, Li W, Feng Y,
Mihailescu MR, Bassell GJ. hnRNP-Q1 represses nascent axon growth in
cortical neurons by inhibiting Gap-43 mRNA translation. Mol Biol Cell. 2015;
27(3):518–34.
123. McDermott SM, Yang L, Halstead JM, Hamilton RS, Meignin C, Davis I.
Drosophila Syncrip modulates the expression of mRNAs encoding key
synaptic proteins required for morphology at the neuromuscular junction.
RNA N Y N. 2014;20(10):1593–606.
124. Chen H-H, Yu H-I, Chiang W-C, Lin Y-D, Shia B-C, Tarn W-Y. hnRNP Q
regulates Cdc42-mediated neuronal morphogenesis. Mol Cell Biol. 2012;
32(12):2224–38.
125. Duning K, Buck F, Barnekow A, Kremerskothen J. SYNCRIP, a component of
dendritically localized mRNPs, binds to the translation regulator BC200 RNA.
J Neurochem. 2008;105(2):351–9.
126. Schneider T, Ziòłkowska B, Gieryk A, Tyminska A, Przewłocki R. Prenatal
exposure to valproic acid disturbs the enkephalinergic system functioning,
basal hedonic tone, and emotional responses in an animal model of autism.
Psychopharmacology. 2007;193(4):547–55.
127. Dobi A, Szemes M, Lee C, Palkovits M, Lim F, Gyorgy A, et al. AUF1 is
expressed in the developing brain, binds to AT-rich double-stranded DNA,
and regulates enkephalin gene expression. J Biol Chem. 2006;281(39):
28889–900.
128. Leirer DJ, Iyegbe CO, Di Forti M, Patel H, Carra E, Fraietta S, et al. Differential
gene expression analysis in blood of first episode psychosis patients.
Schizophr Res. 2019;209:88–97.
129. Servadio M, Manduca A, Melancia F, Leboffe L, Schiavi S, Campolongo P,
Palmery M, Ascenzi P, di Masi A, Trezza V. Impaired repair of DNA damage is
associated with autistic-like traits in rats prenatally exposed to valproic acid.
Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2018;28(1):
85–96.
130. Hong Z, Jiang J, Ma J, Dai S, Xu T, Li H, Yasui A. The role of hnRPUL1
involved in DNA damage response is related to PARP1. PLoS One. 2013;8(4):
e60208.
131. Polo SE, Blackford AN, Chapman JR, Baskcomb L, Gravel S, Rusch A, Thomas
A, Blundred R, Smith P, Kzhyshkowska J, Dobner T, Taylor AMR, Turnell AS,
Stewart GS, Grand RJ, Jackson SP. Regulation of DNA-end resection by
hnRNPU-like proteins promotes DNA double-strand break signaling and
repair. Mol Cell. 2012;45(4):505–16.
132. Markkanen E, Meyer U, Dianov GL. DNA damage and repair in schizophrenia
and autism: implications for cancer comorbidity and beyond. Int J Mol Sci
2016;17(6).
133. Lampasona AA, Czaplinski K. Hnrnpab regulates neural cell motility through
transcription of Eps8. RNA N Y N. 2019;25(1):45–59.
134. Sinnamon JR, Waddell CB, Nik S, Chen EI, Czaplinski K. Hnrpab regulates
neural development and neuron cell survival after glutamate stimulation.
RNA N Y N. 2012;18(4):704–19.
135. White R, Gonsior C, Bauer NM, Krämer-Albers E-M, Luhmann HJ, Trotter J.
Heterogeneous nuclear ribonucleoprotein (hnRNP) F is a novel component
of oligodendroglial RNA transport granules contributing to regulation of
myelin basic protein (MBP) synthesis. J Biol Chem. 2012;287(3):1742–54.
136. Chou M-Y, Rooke N, Turck CW, Black DL. hnRNP H is a component of a
splicing enhancer complex that activates a c-src alternative exon in
neuronal cells. Mol Cell Biol. 1999;19(1):69–77.
137. Latorre E, Torregrossa R, Wood ME, Whiteman M, Harries LW. Mitochondria-
targeted hydrogen sulfide attenuates endothelial senescence by selective
induction of splicing factors HNRNPD and SRSF2. Aging. 2018;10(7):1666–81.
138. GenBank Overview. Available from: https://www.ncbi.nlm.nih.gov/genbank/
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Gillentine et al. Genome Medicine           (2021) 13:63 Page 26 of 26









Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”). 
Springer Nature supports a reasonable amount of sharing of  research papers by authors, subscribers and authorised users (“Users”), for small-
scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By
accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these
purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial. 
These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal
subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription
(to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will
apply. 
We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within
ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not
otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as
detailed in the Privacy Policy. 
While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may
not: 
 
use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access
control;
use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is
otherwise unlawful;
falsely or misleadingly imply or suggest endorsement, approval , sponsorship, or association unless explicitly agreed to by Springer Nature in
writing;
use bots or other automated methods to access the content or redirect messages
override any security feature or exclusionary protocol; or
share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal
content.
 
In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue,
royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal
content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any
other, institutional repository. 
These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or
content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature
may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved. 
To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied
with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law,
including merchantability or fitness for any particular purpose. 
Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed
from third parties. 
If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not
expressly permitted by these Terms, please contact Springer Nature at 
 
onlineservice@springernature.com
 
